US20040013609A1 - Screening method - Google Patents
Screening method Download PDFInfo
- Publication number
- US20040013609A1 US20040013609A1 US10/464,750 US46475003A US2004013609A1 US 20040013609 A1 US20040013609 A1 US 20040013609A1 US 46475003 A US46475003 A US 46475003A US 2004013609 A1 US2004013609 A1 US 2004013609A1
- Authority
- US
- United States
- Prior art keywords
- optionally substituted
- eye
- alkyl
- dimethylxanthine
- xanthine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 106
- 238000012216 screening Methods 0.000 title claims description 11
- 239000000126 substance Substances 0.000 claims abstract description 213
- 230000000694 effects Effects 0.000 claims abstract description 118
- 238000011282 treatment Methods 0.000 claims abstract description 85
- 230000012010 growth Effects 0.000 claims abstract description 54
- 230000004379 myopia Effects 0.000 claims abstract description 53
- 208000001491 myopia Diseases 0.000 claims abstract description 53
- 239000000203 mixture Substances 0.000 claims abstract description 43
- 210000003583 retinal pigment epithelium Anatomy 0.000 claims abstract description 35
- 206010020675 Hypermetropia Diseases 0.000 claims abstract description 34
- 230000004305 hyperopia Effects 0.000 claims abstract description 34
- 201000006318 hyperopia Diseases 0.000 claims abstract description 34
- 230000003405 preventing effect Effects 0.000 claims abstract description 34
- 230000004323 axial length Effects 0.000 claims abstract description 30
- 210000001519 tissue Anatomy 0.000 claims abstract description 28
- 238000002360 preparation method Methods 0.000 claims abstract description 21
- 230000002265 prevention Effects 0.000 claims abstract description 16
- 210000000981 epithelium Anatomy 0.000 claims abstract description 8
- 230000002503 metabolic effect Effects 0.000 claims abstract description 7
- 230000002207 retinal effect Effects 0.000 claims abstract description 3
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 119
- 210000003786 sclera Anatomy 0.000 claims description 85
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims description 83
- PFWLFWPASULGAN-UHFFFAOYSA-N 7-methylxanthine Chemical compound N1C(=O)NC(=O)C2=C1N=CN2C PFWLFWPASULGAN-UHFFFAOYSA-N 0.000 claims description 71
- -1 carboxy, hydroxy Chemical group 0.000 claims description 68
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 60
- 229960001948 caffeine Drugs 0.000 claims description 56
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 56
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 53
- 229940075420 xanthine Drugs 0.000 claims description 47
- 229960000278 theophylline Drugs 0.000 claims description 46
- 102000008186 Collagen Human genes 0.000 claims description 40
- 108010035532 Collagen Proteins 0.000 claims description 40
- 229920001436 collagen Polymers 0.000 claims description 40
- 229960003067 cystine Drugs 0.000 claims description 38
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 claims description 36
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims description 35
- 235000001014 amino acid Nutrition 0.000 claims description 34
- 150000001413 amino acids Chemical class 0.000 claims description 34
- 230000001965 increasing effect Effects 0.000 claims description 34
- MRWQRJMESRRJJB-UHFFFAOYSA-N pentifylline Chemical compound O=C1N(CCCCCC)C(=O)N(C)C2=C1N(C)C=N2 MRWQRJMESRRJJB-UHFFFAOYSA-N 0.000 claims description 33
- 241001465754 Metazoa Species 0.000 claims description 31
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 28
- 125000001072 heteroaryl group Chemical group 0.000 claims description 28
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 25
- 125000005129 aryl carbonyl group Chemical group 0.000 claims description 25
- 125000003107 substituted aryl group Chemical group 0.000 claims description 25
- 210000002808 connective tissue Anatomy 0.000 claims description 24
- 239000001257 hydrogen Substances 0.000 claims description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 23
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 22
- 229910052736 halogen Inorganic materials 0.000 claims description 21
- 150000002367 halogens Chemical class 0.000 claims description 21
- 125000001153 fluoro group Chemical group F* 0.000 claims description 20
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 19
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 claims description 19
- 125000002346 iodo group Chemical group I* 0.000 claims description 19
- 125000001246 bromo group Chemical group Br* 0.000 claims description 18
- KSCFJBIXMNOVSH-UHFFFAOYSA-N dyphylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CC(O)CO)C=N2 KSCFJBIXMNOVSH-UHFFFAOYSA-N 0.000 claims description 18
- 238000002571 electroretinography Methods 0.000 claims description 18
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 18
- 229960004559 theobromine Drugs 0.000 claims description 18
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 17
- 125000003601 C2-C6 alkynyl group Chemical class 0.000 claims description 17
- QUNWUDVFRNGTCO-UHFFFAOYSA-N Paraxanthine Natural products N1C(=O)N(C)C(=O)C2=C1N=CN2C QUNWUDVFRNGTCO-UHFFFAOYSA-N 0.000 claims description 17
- NSMXQKNUPPXBRG-UHFFFAOYSA-N 1-(5-hydroxyhexyl)-3,7-dimethyl-3,7-dihydro-1H-purine-2,6-dione Chemical compound O=C1N(CCCCC(O)C)C(=O)N(C)C2=C1N(C)C=N2 NSMXQKNUPPXBRG-UHFFFAOYSA-N 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 229960002464 fluoxetine Drugs 0.000 claims description 16
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 16
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims description 15
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims description 14
- MVOYJPOZRLFTCP-UHFFFAOYSA-N 1-methyl-7H-xanthine Chemical compound O=C1N(C)C(=O)NC2=C1NC=N2 MVOYJPOZRLFTCP-UHFFFAOYSA-N 0.000 claims description 14
- 239000000556 agonist Substances 0.000 claims description 14
- 125000004104 aryloxy group Chemical group 0.000 claims description 14
- 230000007423 decrease Effects 0.000 claims description 14
- GMSNIKWWOQHZGF-UHFFFAOYSA-N 3-methyl-9H-xanthine Chemical compound O=C1NC(=O)N(C)C2=C1N=CN2 GMSNIKWWOQHZGF-UHFFFAOYSA-N 0.000 claims description 13
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 13
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims description 13
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 13
- 229960003104 ornithine Drugs 0.000 claims description 13
- RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical compound N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 claims description 12
- NWXULHNEYYFVMF-UHFFFAOYSA-N albifylline Chemical compound O=C1N(CCCCC(C)(C)O)C(=O)N(C)C2=C1NC=N2 NWXULHNEYYFVMF-UHFFFAOYSA-N 0.000 claims description 12
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 11
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims description 11
- QVAYTZAGDQIWMB-UHFFFAOYSA-N 7-methyl-1,3-dipropylpurine-2,6-dione Chemical compound O=C1N(CCC)C(=O)N(CCC)C2=C1N(C)C=N2 QVAYTZAGDQIWMB-UHFFFAOYSA-N 0.000 claims description 11
- 125000005226 heteroaryloxycarbonyl group Chemical group 0.000 claims description 11
- 229960002371 pentifylline Drugs 0.000 claims description 11
- 102000005962 receptors Human genes 0.000 claims description 11
- 108020003175 receptors Proteins 0.000 claims description 11
- 108091052345 ryanodine receptor (TC 1.A.3.1) family Proteins 0.000 claims description 11
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 claims description 10
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical group [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 10
- RBQOQRRFDPXAGN-UHFFFAOYSA-N Propentofylline Chemical compound CN1C(=O)N(CCCCC(C)=O)C(=O)C2=C1N=CN2CCC RBQOQRRFDPXAGN-UHFFFAOYSA-N 0.000 claims description 10
- 102000001424 Ryanodine receptors Human genes 0.000 claims description 10
- 229910001424 calcium ion Inorganic materials 0.000 claims description 10
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims description 10
- 239000000018 receptor agonist Substances 0.000 claims description 10
- 229940044601 receptor agonist Drugs 0.000 claims description 10
- 229910021653 sulphate ion Inorganic materials 0.000 claims description 10
- 125000006649 (C2-C20) alkynyl group Chemical group 0.000 claims description 9
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 claims description 9
- OEPXIQLEKWHAGE-UHFFFAOYSA-N 8-(dicyclopropylmethyl)-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C1CC1)C1CC1 OEPXIQLEKWHAGE-UHFFFAOYSA-N 0.000 claims description 9
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 claims description 9
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 claims description 9
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 9
- UGCOFEOEBHUEHA-JXMROGBWSA-N (e)-3-[4-(2,6-dioxo-1,3-dipropyl-7h-purin-8-yl)phenyl]prop-2-enoic acid Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1=CC=C(\C=C\C(O)=O)C=C1 UGCOFEOEBHUEHA-JXMROGBWSA-N 0.000 claims description 8
- HJPRDDKCXVCFOH-UHFFFAOYSA-N 1,3-dibutyl-7-(2-oxopropyl)purine-2,6-dione Chemical compound O=C1N(CCCC)C(=O)N(CCCC)C2=C1N(CC(C)=O)C=N2 HJPRDDKCXVCFOH-UHFFFAOYSA-N 0.000 claims description 8
- AXDZQZQUNHYUGL-UHFFFAOYSA-N 1-butyl-3-propyl-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C(=O)N(CCC)C2=C1NC=N2 AXDZQZQUNHYUGL-UHFFFAOYSA-N 0.000 claims description 8
- UQGGPCQNHJCOPS-PKNBQFBNSA-N 8-[(e)-2-(3,4-dimethoxyphenyl)ethenyl]-7-methyl-1,3-dipropylpurine-2,6-dione Chemical compound CN1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1\C=C\C1=CC=C(OC)C(OC)=C1 UQGGPCQNHJCOPS-PKNBQFBNSA-N 0.000 claims description 8
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 8
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- 229960005176 bamifylline Drugs 0.000 claims description 8
- VVUYEFBRTFASAH-UHFFFAOYSA-N bamifylline Chemical compound N=1C=2N(C)C(=O)N(C)C(=O)C=2N(CCN(CCO)CC)C=1CC1=CC=CC=C1 VVUYEFBRTFASAH-UHFFFAOYSA-N 0.000 claims description 8
- 229960002819 diprophylline Drugs 0.000 claims description 8
- HWXIGFIVGWUZAO-UHFFFAOYSA-N doxofylline Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CC1OCCO1 HWXIGFIVGWUZAO-UHFFFAOYSA-N 0.000 claims description 8
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 7
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims description 7
- XKZALMBJTMJPFU-UHFFFAOYSA-N 1,9-dimethyl-3h-purine-2,6-dione Chemical compound N1C(=O)N(C)C(=O)C2=C1N(C)C=N2 XKZALMBJTMJPFU-UHFFFAOYSA-N 0.000 claims description 7
- IORPOFJLSIHJOG-UHFFFAOYSA-N 3,7-dimethyl-1-prop-2-ynylpurine-2,6-dione Chemical compound CN1C(=O)N(CC#C)C(=O)C2=C1N=CN2C IORPOFJLSIHJOG-UHFFFAOYSA-N 0.000 claims description 7
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 claims description 7
- 229960003679 brimonidine Drugs 0.000 claims description 7
- SIQPXVQCUCHWDI-UHFFFAOYSA-N enprofylline Chemical compound O=C1NC(=O)N(CCC)C2=C1NC=N2 SIQPXVQCUCHWDI-UHFFFAOYSA-N 0.000 claims description 7
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 claims description 7
- 229960001160 latanoprost Drugs 0.000 claims description 7
- LXJSJIXZOAMHTG-UHFFFAOYSA-N 4-(1,3-dimethyl-2,6-dioxo-7h-purin-8-yl)benzenesulfonic acid Chemical compound N1C=2C(=O)N(C)C(=O)N(C)C=2N=C1C1=CC=C(S(O)(=O)=O)C=C1 LXJSJIXZOAMHTG-UHFFFAOYSA-N 0.000 claims description 6
- NWPRCRWQMGIBOT-UHFFFAOYSA-N 7-(2-hydroxyethyl)-1,3-dimethylpurine-2,6-dione Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CCO)C=N2 NWPRCRWQMGIBOT-UHFFFAOYSA-N 0.000 claims description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- 108090000028 Neprilysin Proteins 0.000 claims description 6
- 102000003729 Neprilysin Human genes 0.000 claims description 6
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 6
- 229960000830 captopril Drugs 0.000 claims description 6
- IAVUPMFITXYVAF-XPUUQOCRSA-N dorzolamide Chemical compound CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 IAVUPMFITXYVAF-XPUUQOCRSA-N 0.000 claims description 6
- 210000002950 fibroblast Anatomy 0.000 claims description 6
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 claims description 6
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- 230000002195 synergetic effect Effects 0.000 claims description 6
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 5
- QSXXLDDWVCEBFP-UHFFFAOYSA-N 7-(ethoxymethyl)-1-(5-hydroxy-5-methylhexyl)-3-methylpurine-2,6-dione Chemical compound CN1C(=O)N(CCCCC(C)(C)O)C(=O)C2=C1N=CN2COCC QSXXLDDWVCEBFP-UHFFFAOYSA-N 0.000 claims description 5
- PBENJWAFQLORQL-UHFFFAOYSA-N 8-chloro-1-phenyl-[1,2,4]triazolo[4,3-a]quinoxalin-4-amine Chemical compound N=1N=C2C(N)=NC3=CC=C(Cl)C=C3N2C=1C1=CC=CC=C1 PBENJWAFQLORQL-UHFFFAOYSA-N 0.000 claims description 5
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 claims description 5
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 239000003889 eye drop Substances 0.000 claims description 5
- 229940012356 eye drops Drugs 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 5
- 230000000699 topical effect Effects 0.000 claims description 5
- NSMXQKNUPPXBRG-SECBINFHSA-N (R)-lisofylline Chemical compound O=C1N(CCCC[C@H](O)C)C(=O)N(C)C2=C1N(C)C=N2 NSMXQKNUPPXBRG-SECBINFHSA-N 0.000 claims description 4
- GEADEWLQJFNDLL-GNQOZLGHSA-N (z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(e,3s)-3-hydroxy-5-phenyloct-1-enyl]cyclopentyl]hept-5-enoic acid Chemical compound C(/[C@@H](O)CC(CCC)C=1C=CC=CC=1)=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O GEADEWLQJFNDLL-GNQOZLGHSA-N 0.000 claims description 4
- JGZRPRSJSQLFBO-FWPUOYPASA-N 17-phenyl-trinor-PGF2alpha isopropyl ester Chemical group CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 JGZRPRSJSQLFBO-FWPUOYPASA-N 0.000 claims description 4
- HCYFGRCYSCXKNQ-UHFFFAOYSA-N 2-(1,3-dimethyl-2,6-dioxo-7-purinyl)acetic acid Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CC(O)=O)C=N2 HCYFGRCYSCXKNQ-UHFFFAOYSA-N 0.000 claims description 4
- SEIRRUDMPNNSCY-UHFFFAOYSA-N 2-amino-2-methylpropan-1-ol;1,3-dimethyl-7h-purine-2,6-dione Chemical compound CC(C)(N)CO.O=C1N(C)C(=O)N(C)C2=C1NC=N2 SEIRRUDMPNNSCY-UHFFFAOYSA-N 0.000 claims description 4
- WXFJHNDXYIDTAF-UHFFFAOYSA-N 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol;2-(1,3-dimethyl-2,6-dioxopurin-7-yl)ethyl hydrogen sulfate Chemical compound CC1=NC=C(CO)C(CO)=C1O.O=C1N(C)C(=O)N(C)C2=C1N(CCOS(O)(=O)=O)C=N2 WXFJHNDXYIDTAF-UHFFFAOYSA-N 0.000 claims description 4
- DVKVZPIRWWREJC-UHFFFAOYSA-N 4-chloro-3-ethylphenol Chemical compound CCC1=CC(O)=CC=C1Cl DVKVZPIRWWREJC-UHFFFAOYSA-N 0.000 claims description 4
- HIYAVKIYRIFSCZ-CYEMHPAKSA-N 5-(methylamino)-2-[[(2S,3R,5R,6S,8R,9R)-3,5,9-trimethyl-2-[(2S)-1-oxo-1-(1H-pyrrol-2-yl)propan-2-yl]-1,7-dioxaspiro[5.5]undecan-8-yl]methyl]-1,3-benzoxazole-4-carboxylic acid Chemical compound O=C([C@@H](C)[C@H]1O[C@@]2([C@@H](C[C@H]1C)C)O[C@@H]([C@@H](CC2)C)CC=1OC2=CC=C(C(=C2N=1)C(O)=O)NC)C1=CC=CN1 HIYAVKIYRIFSCZ-CYEMHPAKSA-N 0.000 claims description 4
- KVZYKZBYZVKXNI-STOWLHSFSA-N 7-[2-(diethylamino)ethyl]-1,3-dimethylpurine-2,6-dione;[(1r,4s)-7,7-dimethyl-3-oxo-4-bicyclo[2.2.1]heptanyl]methanesulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C.CN1C(=O)N(C)C(=O)C2=C1N=CN2CCN(CC)CC KVZYKZBYZVKXNI-STOWLHSFSA-N 0.000 claims description 4
- PJBFVWGQFLYWCB-QUYAXPHCSA-N 7805s5hihx Chemical compound C([C@H](C[C@@H](C1)C2)C3)C2C31C1=NC(N(C(N(CCC)C2=O)=O)CCC)=C2N1 PJBFVWGQFLYWCB-QUYAXPHCSA-N 0.000 claims description 4
- SENJBFBVCXOUFE-UHFFFAOYSA-N 8-(2-amino-4-chlorophenyl)-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1=CC=C(Cl)C=C1N SENJBFBVCXOUFE-UHFFFAOYSA-N 0.000 claims description 4
- WBWFIUAVMCNYPG-BQYQJAHWSA-N 8-(3-chlorostyryl)caffeine Chemical compound N=1C=2N(C)C(=O)N(C)C(=O)C=2N(C)C=1\C=C\C1=CC=CC(Cl)=C1 WBWFIUAVMCNYPG-BQYQJAHWSA-N 0.000 claims description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N Adenosine Natural products C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 4
- 102400000059 Arg-vasopressin Human genes 0.000 claims description 4
- 101800001144 Arg-vasopressin Proteins 0.000 claims description 4
- 102400000967 Bradykinin Human genes 0.000 claims description 4
- 101800004538 Bradykinin Proteins 0.000 claims description 4
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 4
- 125000003860 C1-C20 alkoxy group Chemical group 0.000 claims description 4
- VJGGHXVGBSZVMZ-QIZQQNKQSA-N Cloprostenol Chemical compound C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(O)=O)OC1=CC=CC(Cl)=C1 VJGGHXVGBSZVMZ-QIZQQNKQSA-N 0.000 claims description 4
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims description 4
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims description 4
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 claims description 4
- 102100033467 L-selectin Human genes 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 claims description 4
- 102000002808 Pituitary adenylate cyclase-activating polypeptide Human genes 0.000 claims description 4
- 108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 claims description 4
- 229940127473 Prostaglandin Receptor Agonists Drugs 0.000 claims description 4
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 claims description 4
- FVECELJHCSPHKY-UHFFFAOYSA-N Veratridine Natural products C1=C(OC)C(OC)=CC=C1C(=O)OC1C2(O)OC34CC5(O)C(CN6C(CCC(C)C6)C6(C)O)C6(O)C(O)CC5(O)C4CCC2C3(C)CC1 FVECELJHCSPHKY-UHFFFAOYSA-N 0.000 claims description 4
- 229950003769 acefylline Drugs 0.000 claims description 4
- 229960005305 adenosine Drugs 0.000 claims description 4
- 239000002597 adenosine A2 receptor agonist Substances 0.000 claims description 4
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 claims description 4
- 229950006129 albifylline Drugs 0.000 claims description 4
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 claims description 4
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims description 4
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 claims description 4
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims description 4
- 229940073654 bufylline Drugs 0.000 claims description 4
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 claims description 4
- 229960004064 bumetanide Drugs 0.000 claims description 4
- ZGNRRVAPHPANFI-UHFFFAOYSA-N cafaminol Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=C(N(CCO)C)N2C ZGNRRVAPHPANFI-UHFFFAOYSA-N 0.000 claims description 4
- 229950003668 cafaminol Drugs 0.000 claims description 4
- 235000020964 calcitriol Nutrition 0.000 claims description 4
- 239000011612 calcitriol Substances 0.000 claims description 4
- 229960005084 calcitriol Drugs 0.000 claims description 4
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 claims description 4
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 claims description 4
- 229960004484 carbachol Drugs 0.000 claims description 4
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 claims description 4
- 210000000170 cell membrane Anatomy 0.000 claims description 4
- 229960004409 cloprostenol Drugs 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 229950004687 denbufylline Drugs 0.000 claims description 4
- 229960002986 dinoprostone Drugs 0.000 claims description 4
- 229960004483 doxofylline Drugs 0.000 claims description 4
- 229960000505 etamiphylline Drugs 0.000 claims description 4
- 229960005387 etofylline Drugs 0.000 claims description 4
- WWSWYXNVCBLWNZ-QIZQQNKQSA-N fluprostenol Chemical compound C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(O)=O)OC1=CC=CC(C(F)(F)F)=C1 WWSWYXNVCBLWNZ-QIZQQNKQSA-N 0.000 claims description 4
- 229950009951 fluprostenol Drugs 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- HNPFPERDNWXAGS-NFVOFSAMSA-N latanoprost free acid Chemical compound C([C@@H](O)CCC=1C=CC=CC=1)C[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O HNPFPERDNWXAGS-NFVOFSAMSA-N 0.000 claims description 4
- 229950011606 lisofylline Drugs 0.000 claims description 4
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 claims description 4
- ZFLWDHHVRRZMEI-UHFFFAOYSA-N methyl 2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C([N+]([O-])=O)C1C1=CC=CC=C1C(F)(F)F ZFLWDHHVRRZMEI-UHFFFAOYSA-N 0.000 claims description 4
- FIQGIOAELHTLHM-UHFFFAOYSA-N n-(2-aminoethyl)-2-[4-(2,6-dioxo-1,3-dipropyl-7h-purin-8-yl)phenoxy]acetamide Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1=CC=C(OCC(=O)NCCN)C=C1 FIQGIOAELHTLHM-UHFFFAOYSA-N 0.000 claims description 4
- 229960000916 niflumic acid Drugs 0.000 claims description 4
- 229960001476 pentoxifylline Drugs 0.000 claims description 4
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims description 4
- UFTCZKMBJOPXDM-XXFCQBPRSA-N pituitary adenylate cyclase-activating polypeptide Chemical compound C([C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 UFTCZKMBJOPXDM-XXFCQBPRSA-N 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims description 4
- 229950000906 pyridofylline Drugs 0.000 claims description 4
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 claims description 4
- 229950005741 rolipram Drugs 0.000 claims description 4
- 229960001603 tamoxifen Drugs 0.000 claims description 4
- IXFPJGBNCFXKPI-FSIHEZPISA-N thapsigargin Chemical compound CCCC(=O)O[C@H]1C[C@](C)(OC(C)=O)[C@H]2[C@H](OC(=O)CCCCCCC)[C@@H](OC(=O)C(\C)=C/C)C(C)=C2[C@@H]2OC(=O)[C@@](C)(O)[C@]21O IXFPJGBNCFXKPI-FSIHEZPISA-N 0.000 claims description 4
- 229950011536 torbafylline Drugs 0.000 claims description 4
- FVECELJHCSPHKY-JLSHOZRYSA-N veratridine Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)O[C@@H]1[C@@]2(O)O[C@]34C[C@@]5(O)[C@H](CN6[C@@H](CC[C@H](C)C6)[C@@]6(C)O)[C@]6(O)[C@@H](O)C[C@@]5(O)[C@@H]4CC[C@H]2[C@]3(C)CC1 FVECELJHCSPHKY-JLSHOZRYSA-N 0.000 claims description 4
- REZGGXNDEMKIQB-UHFFFAOYSA-N zaprinast Chemical compound CCCOC1=CC=CC=C1C1=NC(=O)C2=NNNC2=N1 REZGGXNDEMKIQB-UHFFFAOYSA-N 0.000 claims description 4
- 229950005371 zaprinast Drugs 0.000 claims description 4
- YFGBQHOOROIVKG-BHDDXSALSA-N (2R)-2-[[(2R)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound C([C@H](C(=O)N[C@H](CCSC)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 YFGBQHOOROIVKG-BHDDXSALSA-N 0.000 claims description 3
- JFLUCCKXAYBETQ-VIFPVBQESA-N (4s)-4-(2-methylpropylamino)-7,7-dioxo-5,6-dihydro-4h-thieno[2,3-b]thiopyran-2-sulfonamide Chemical compound CC(C)CN[C@H]1CCS(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 JFLUCCKXAYBETQ-VIFPVBQESA-N 0.000 claims description 3
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims description 3
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 claims description 3
- IWALGNIFYOBRKC-UHFFFAOYSA-N 4-(2,6-dioxo-1,3-dipropyl-7h-purin-8-yl)benzenesulfonic acid Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1=CC=C(S(O)(=O)=O)C=C1 IWALGNIFYOBRKC-UHFFFAOYSA-N 0.000 claims description 3
- JFLUCCKXAYBETQ-UHFFFAOYSA-N 4-(2-methylpropylamino)-7,7-dioxo-5,6-dihydro-4h-thieno[2,3-b]thiopyran-2-sulfonamide Chemical compound CC(C)CNC1CCS(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 JFLUCCKXAYBETQ-UHFFFAOYSA-N 0.000 claims description 3
- OSCRZLORGNTZPM-UHFFFAOYSA-N 7,9-dimethyl-3,8-dihydropurine-2,6-dione Chemical compound N1C(=O)NC(=O)C2=C1N(C)CN2C OSCRZLORGNTZPM-UHFFFAOYSA-N 0.000 claims description 3
- KYHQZNGJUGFTGR-LURJTMIESA-N 7-[(2s)-2-hydroxypropyl]-1,3-dimethylpurine-2,6-dione Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C[C@@H](O)C KYHQZNGJUGFTGR-LURJTMIESA-N 0.000 claims description 3
- YZYPLLAMOKYMRE-UHFFFAOYSA-N 7-propyl-3h-purine-2,6-dione Chemical compound N1C(=O)NC(=O)C2=C1N=CN2CCC YZYPLLAMOKYMRE-UHFFFAOYSA-N 0.000 claims description 3
- SCVHFRLUNIOSGI-UHFFFAOYSA-N 8-cyclopentyl-1,3-dimethyl-7H-purine-2,6-dione Chemical compound N1C=2C(=O)N(C)C(=O)N(C)C=2N=C1C1CCCC1 SCVHFRLUNIOSGI-UHFFFAOYSA-N 0.000 claims description 3
- JAFHXBXIPLCFRN-UHFFFAOYSA-N 8-cyclopentyl-1,3-dimethyl-7h-purine-2,6-dione;3,9-dimethylpurine-2,6-dione Chemical compound CN1C(=O)NC(=O)C2=C1N(C)C=N2.N1C=2C(=O)N(C)C(=O)N(C)C=2N=C1C1CCCC1 JAFHXBXIPLCFRN-UHFFFAOYSA-N 0.000 claims description 3
- 239000005541 ACE inhibitor Substances 0.000 claims description 3
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 3
- 229940121707 Calmodulin antagonist Drugs 0.000 claims description 3
- 241000723346 Cinnamomum camphora Species 0.000 claims description 3
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 claims description 3
- 108050009340 Endothelin Proteins 0.000 claims description 3
- 102000002045 Endothelin Human genes 0.000 claims description 3
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 3
- 102400000243 Leu-enkephalin Human genes 0.000 claims description 3
- 108010022337 Leucine Enkephalin Proteins 0.000 claims description 3
- 102400000988 Met-enkephalin Human genes 0.000 claims description 3
- 108010042237 Methionine Enkephalin Proteins 0.000 claims description 3
- WPNJAUFVNXKLIM-UHFFFAOYSA-N Moxonidine Chemical compound COC1=NC(C)=NC(Cl)=C1NC1=NCCN1 WPNJAUFVNXKLIM-UHFFFAOYSA-N 0.000 claims description 3
- 108050002826 Neuropeptide Y Receptor Proteins 0.000 claims description 3
- 102000012301 Neuropeptide Y receptor Human genes 0.000 claims description 3
- 102100038991 Neuropeptide Y receptor type 2 Human genes 0.000 claims description 3
- 101710197945 Neuropeptide Y receptor type 2 Proteins 0.000 claims description 3
- 108050008995 Prostaglandin F receptors Proteins 0.000 claims description 3
- KYHQZNGJUGFTGR-UHFFFAOYSA-N Proxyphylline Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2CC(O)C KYHQZNGJUGFTGR-UHFFFAOYSA-N 0.000 claims description 3
- 101150058615 Ptger1 gene Proteins 0.000 claims description 3
- PJBFVWGQFLYWCB-UHFFFAOYSA-N Rolofylline Chemical compound C1C(CC(C2)C3)CC3C12C1=NC(N(C(N(CCC)C2=O)=O)CCC)=C2N1 PJBFVWGQFLYWCB-UHFFFAOYSA-N 0.000 claims description 3
- 101150084577 SST2 gene Proteins 0.000 claims description 3
- 102000005157 Somatostatin Human genes 0.000 claims description 3
- 108010056088 Somatostatin Proteins 0.000 claims description 3
- 108090000300 Thromboxane Receptors Proteins 0.000 claims description 3
- 102000003938 Thromboxane Receptors Human genes 0.000 claims description 3
- 229930003316 Vitamin D Natural products 0.000 claims description 3
- 108010041395 alpha-Endorphin Proteins 0.000 claims description 3
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 3
- 229960002610 apraclonidine Drugs 0.000 claims description 3
- IEJXVRYNEISIKR-UHFFFAOYSA-N apraclonidine Chemical compound ClC1=CC(N)=CC(Cl)=C1NC1=NCCN1 IEJXVRYNEISIKR-UHFFFAOYSA-N 0.000 claims description 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 3
- 150000001668 calcitriol derivatives Chemical class 0.000 claims description 3
- 229960000846 camphor Drugs 0.000 claims description 3
- 229930008380 camphor Natural products 0.000 claims description 3
- ZTWZVMIYIIVABD-OEMFJLHTSA-N candoxatril Chemical compound C([C@@H](COCCOC)C(=O)OC=1C=C2CCCC2=CC=1)C1(C(=O)N[C@@H]2CC[C@@H](CC2)C(O)=O)CCCC1 ZTWZVMIYIIVABD-OEMFJLHTSA-N 0.000 claims description 3
- 229950004548 candoxatril Drugs 0.000 claims description 3
- 229960002896 clonidine Drugs 0.000 claims description 3
- 239000013256 coordination polymer Substances 0.000 claims description 3
- 235000018417 cysteine Nutrition 0.000 claims description 3
- RFWZESUMWJKKRN-UHFFFAOYSA-N dapiprazole Chemical compound CC1=CC=CC=C1N1CCN(CCC=2N3CCCCC3=NN=2)CC1 RFWZESUMWJKKRN-UHFFFAOYSA-N 0.000 claims description 3
- 229960002947 dapiprazole Drugs 0.000 claims description 3
- 229960003933 dorzolamide Drugs 0.000 claims description 3
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims description 3
- 229950000579 enprofylline Drugs 0.000 claims description 3
- 239000000328 estrogen antagonist Substances 0.000 claims description 3
- OUZWUKMCLIBBOG-UHFFFAOYSA-N ethoxzolamide Chemical compound CCOC1=CC=C2N=C(S(N)(=O)=O)SC2=C1 OUZWUKMCLIBBOG-UHFFFAOYSA-N 0.000 claims description 3
- 229950005098 ethoxzolamide Drugs 0.000 claims description 3
- 238000005342 ion exchange Methods 0.000 claims description 3
- URLZCHNOLZSCCA-UHFFFAOYSA-N leu-enkephalin Chemical compound C=1C=C(O)C=CC=1CC(N)C(=O)NCC(=O)NCC(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=CC=C1 URLZCHNOLZSCCA-UHFFFAOYSA-N 0.000 claims description 3
- HRLIOXLXPOHXTA-UHFFFAOYSA-N medetomidine Chemical compound C=1C=CC(C)=C(C)C=1C(C)C1=CN=C[N]1 HRLIOXLXPOHXTA-UHFFFAOYSA-N 0.000 claims description 3
- 229960002140 medetomidine Drugs 0.000 claims description 3
- FLOSMHQXBMRNHR-DAXSKMNVSA-N methazolamide Chemical compound CC(=O)\N=C1/SC(S(N)(=O)=O)=NN1C FLOSMHQXBMRNHR-DAXSKMNVSA-N 0.000 claims description 3
- 229960004083 methazolamide Drugs 0.000 claims description 3
- 229960003938 moxonidine Drugs 0.000 claims description 3
- 229960000715 nimodipine Drugs 0.000 claims description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 3
- 229960001528 oxymetazoline Drugs 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 229960004767 proxyphylline Drugs 0.000 claims description 3
- LXPHPKVWHQLBBA-UHFFFAOYSA-N sarafotoxin s6c Chemical compound C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(C(C)CC)NC(=O)C(C(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CCC(N)=O)NC(=O)C(NC(=O)C1NC(=O)C(CC=2C=CC=CC=2)NC(=O)C(CC(N)=O)NC(=O)C(CC(C)C)NC(=O)C2CSSCC(C(NC(CC(N)=O)C(=O)NC(CC(O)=O)C(=O)NC(CCSC)C(=O)NC(C(=O)NC(CC(O)=O)C(=O)NC(CCC(O)=O)C(=O)NC(CCC(O)=O)C(=O)N2)C(C)O)=O)NC(=O)C(C(C)O)NC(=O)C(N)CSSC1)CC1=CN=CN1 LXPHPKVWHQLBBA-UHFFFAOYSA-N 0.000 claims description 3
- 229950004070 sezolamide Drugs 0.000 claims description 3
- 229960000553 somatostatin Drugs 0.000 claims description 3
- 229940075620 somatostatin analogue Drugs 0.000 claims description 3
- 235000019166 vitamin D Nutrition 0.000 claims description 3
- 239000011710 vitamin D Substances 0.000 claims description 3
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 3
- 229940046008 vitamin d Drugs 0.000 claims description 3
- NXSIJWJXMWBCBX-NWKQFZAZSA-N α-endorphin Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 NXSIJWJXMWBCBX-NWKQFZAZSA-N 0.000 claims description 3
- PJFMAVHETLRJHJ-UHFFFAOYSA-N 8-phenyltheophylline Chemical compound N1C=2C(=O)N(C)C(=O)N(C)C=2N=C1C1=CC=CC=C1 PJFMAVHETLRJHJ-UHFFFAOYSA-N 0.000 claims description 2
- 102100040611 Endothelin receptor type B Human genes 0.000 claims description 2
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 claims description 2
- 229960001783 nicardipine Drugs 0.000 claims description 2
- 239000000790 retinal pigment Substances 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 18
- MMWCIQZXVOZEGG-XJTPDSDZSA-N D-myo-Inositol 1,4,5-trisphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H](O)[C@@H]1OP(O)(O)=O MMWCIQZXVOZEGG-XJTPDSDZSA-N 0.000 claims 6
- 210000004877 mucosa Anatomy 0.000 claims 6
- 239000002674 ointment Substances 0.000 claims 6
- 239000007924 injection Substances 0.000 claims 5
- 238000002347 injection Methods 0.000 claims 5
- 238000007910 systemic administration Methods 0.000 claims 5
- 239000007921 spray Substances 0.000 claims 4
- MMWCIQZXVOZEGG-UHFFFAOYSA-N 1,4,5-IP3 Natural products OC1C(O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(O)C1OP(O)(O)=O MMWCIQZXVOZEGG-UHFFFAOYSA-N 0.000 claims 3
- 239000006071 cream Substances 0.000 claims 3
- 239000000839 emulsion Substances 0.000 claims 3
- 239000000499 gel Substances 0.000 claims 3
- 238000002513 implantation Methods 0.000 claims 3
- 239000006210 lotion Substances 0.000 claims 3
- 229940100652 nasal gel Drugs 0.000 claims 3
- 210000002850 nasal mucosa Anatomy 0.000 claims 3
- 229940100657 nasal ointment Drugs 0.000 claims 3
- 239000006072 paste Substances 0.000 claims 3
- 239000011505 plaster Substances 0.000 claims 3
- 230000000063 preceeding effect Effects 0.000 claims 3
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims 2
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 claims 2
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 claims 2
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000007923 nasal drop Substances 0.000 claims 2
- 239000007922 nasal spray Substances 0.000 claims 2
- 229940124530 sulfonamide Drugs 0.000 claims 2
- RYIGNEOBDRVTHA-UHFFFAOYSA-N 8-chlorotheophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Cl)=N2 RYIGNEOBDRVTHA-UHFFFAOYSA-N 0.000 claims 1
- 150000004702 methyl esters Chemical class 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 5
- 210000001508 eye Anatomy 0.000 description 95
- 239000004158 L-cystine Substances 0.000 description 33
- 235000019393 L-cystine Nutrition 0.000 description 33
- 238000012360 testing method Methods 0.000 description 32
- 229940024606 amino acid Drugs 0.000 description 30
- 229930001406 Ryanodine Natural products 0.000 description 22
- JJSYXNQGLHBRRK-SFEDZAPPSA-N ryanodine Chemical compound O([C@@H]1[C@]([C@@]2([C@]3(O)[C@]45O[C@@]2(O)C[C@]([C@]4(CC[C@H](C)[C@H]5O)O)(C)[C@@]31O)C)(O)C(C)C)C(=O)C1=CC=CN1 JJSYXNQGLHBRRK-SFEDZAPPSA-N 0.000 description 22
- 241000196324 Embryophyta Species 0.000 description 15
- 230000002354 daily effect Effects 0.000 description 14
- 239000000463 material Substances 0.000 description 13
- 229920002683 Glycosaminoglycan Polymers 0.000 description 12
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 description 12
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 235000005911 diet Nutrition 0.000 description 12
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 12
- 229960002591 hydroxyproline Drugs 0.000 description 12
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 12
- 238000000605 extraction Methods 0.000 description 11
- 239000011521 glass Substances 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 9
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 9
- 229960000571 acetazolamide Drugs 0.000 description 9
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 9
- 230000037213 diet Effects 0.000 description 9
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 9
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 9
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 9
- 125000003118 aryl group Chemical group 0.000 description 8
- 230000004515 progressive myopia Effects 0.000 description 8
- 235000000891 standard diet Nutrition 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- RRKLQCJIWVQJQJ-ORKOJDGQSA-N (2s,5r)-2,6-diamino-5-hydroxyhexanoic acid;(2s,4r)-4-hydroxypyrrolidine-2-carboxylic acid;(2s)-pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1.O[C@H]1CN[C@H](C(O)=O)C1.NC[C@H](O)CC[C@H](N)C(O)=O RRKLQCJIWVQJQJ-ORKOJDGQSA-N 0.000 description 7
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 7
- 239000011575 calcium Substances 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 239000000049 pigment Substances 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 210000001525 retina Anatomy 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 240000007154 Coffea arabica Species 0.000 description 6
- 244000228088 Cola acuminata Species 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- 150000002430 hydrocarbons Chemical group 0.000 description 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 235000016795 Cola Nutrition 0.000 description 5
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 5
- MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 description 5
- 210000004087 cornea Anatomy 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000001493 electron microscopy Methods 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 238000011835 investigation Methods 0.000 description 5
- 230000004423 myopia development Effects 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- FFBDFADSZUINTG-UHFFFAOYSA-N DPCPX Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1CCCC1 FFBDFADSZUINTG-UHFFFAOYSA-N 0.000 description 4
- 102000016611 Proteoglycans Human genes 0.000 description 4
- 108010067787 Proteoglycans Proteins 0.000 description 4
- 0 [1*]N1C(=O)C2=C(N([3*])C1=O)N([9*])C([8*])=N2.[1*]N1C(=O)C2=C(N([3*])C1=O)N([9*])C([8*])N2[7*].[1*]N1C(=O)C2=C(N=C([8*])N2[7*])N([3*])C1=O Chemical compound [1*]N1C(=O)C2=C(N([3*])C1=O)N([9*])C([8*])=N2.[1*]N1C(=O)C2=C(N([3*])C1=O)N([9*])C([8*])N2[7*].[1*]N1C(=O)C2=C(N=C([8*])N2[7*])N([3*])C1=O 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 235000016213 coffee Nutrition 0.000 description 4
- 235000013353 coffee beverage Nutrition 0.000 description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000005684 electric field Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 238000011866 long-term treatment Methods 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 229930194542 Keto Natural products 0.000 description 3
- 239000004201 L-cysteine Substances 0.000 description 3
- 235000013878 L-cysteine Nutrition 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241001122767 Theaceae Species 0.000 description 3
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 3
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 3
- UFZTZBNSLXELAL-IOSLPCCCSA-N adenosine 5'-[beta,gamma-methylene]triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)CP(O)(O)=O)[C@@H](O)[C@H]1O UFZTZBNSLXELAL-IOSLPCCCSA-N 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- SWLVFNYSXGMGBS-UHFFFAOYSA-N ammonium bromide Chemical compound [NH4+].[Br-] SWLVFNYSXGMGBS-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 230000006806 disease prevention Effects 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 3
- 239000000413 hydrolysate Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 125000000468 ketone group Chemical group 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 3
- 230000009596 postnatal growth Effects 0.000 description 3
- 239000004575 stone Substances 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- ZLPPPFWZUAKOBV-SDBHATRESA-N (2r,3r,4s,5r)-2-(6-amino-8-anilinopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=CC=CC=1NC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O ZLPPPFWZUAKOBV-SDBHATRESA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- MGUBQPRSQWCLCX-UHFFFAOYSA-N 3,7-dimethylpurine-2,6-dione Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C.CN1C(=O)NC(=O)C2=C1N=CN2C MGUBQPRSQWCLCX-UHFFFAOYSA-N 0.000 description 2
- DHNIKYWYTSMDDA-UHFFFAOYSA-N 9-Methylxanthine Chemical compound N1C(=O)NC(=O)C2=C1N(C)C=N2 DHNIKYWYTSMDDA-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 235000021533 Beta vulgaris Nutrition 0.000 description 2
- 241000335053 Beta vulgaris Species 0.000 description 2
- 235000011824 Cola pachycarpa Nutrition 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 102100032122 Ryanodine receptor 1 Human genes 0.000 description 2
- 108050005124 Ryanodine receptor 1 Proteins 0.000 description 2
- 240000000111 Saccharum officinarum Species 0.000 description 2
- 235000007201 Saccharum officinarum Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000001078 anti-cholinergic effect Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 239000010779 crude oil Substances 0.000 description 2
- 229960004132 diethyl ether Drugs 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 230000003291 dopaminomimetic effect Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 150000002085 enols Chemical class 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- QKFJKGMPGYROCL-UHFFFAOYSA-N phenyl isothiocyanate Chemical compound S=C=NC1=CC=CC=C1 QKFJKGMPGYROCL-UHFFFAOYSA-N 0.000 description 2
- RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 description 2
- 229960004633 pirenzepine Drugs 0.000 description 2
- 229960002934 propentofylline Drugs 0.000 description 2
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000009958 sewing Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000014214 soft drink Nutrition 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000005556 structure-activity relationship Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 235000005282 vitamin D3 Nutrition 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- FPJHWYCPAOPVIV-VOZMEZHOSA-N (2R,3S,4R,5R,6R)-6-[(2R,3R,4R,5R,6R)-5-acetamido-2-(hydroxymethyl)-6-methoxy-3-sulfooxyoxan-4-yl]oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound CO[C@@H]1O[C@H](CO)[C@H](OS(O)(=O)=O)[C@H](O[C@@H]2O[C@H]([C@@H](OC)[C@H](O)[C@H]2O)C(O)=O)[C@H]1NC(C)=O FPJHWYCPAOPVIV-VOZMEZHOSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- OFQFBKMBTAWSIW-UHFFFAOYSA-N 1-methyl-3,7-dihydropurine-2,6-dione;1,3,7-trimethylpurine-2,6-dione Chemical compound O=C1N(C)C(=O)NC2=C1NC=N2.CN1C(=O)N(C)C(=O)C2=C1N=CN2C OFQFBKMBTAWSIW-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- WMRMJHZVMJPUOA-UHFFFAOYSA-N 3,7-dihydropurine-2,6-dione 3-methyl-7H-purine-2,6-dione Chemical compound CN1C(NC(C=2NC=NC12)=O)=O.N1C(=O)NC=2N=CNC2C1=O WMRMJHZVMJPUOA-UHFFFAOYSA-N 0.000 description 1
- AWHJRYCAEQDAKN-UHFFFAOYSA-N 3,7-dihydropurine-2,6-dione;1,3-dimethyl-7h-purine-2,6-dione Chemical compound O=C1NC(=O)NC2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 AWHJRYCAEQDAKN-UHFFFAOYSA-N 0.000 description 1
- KYWKJKVQLGANBH-UHFFFAOYSA-N 3-butyl-1-methyl-7h-purine-2,6-dione Chemical compound O=C1N(C)C(=O)N(CCCC)C2=C1NC=N2 KYWKJKVQLGANBH-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- FDBKULMUJDBIFZ-UHFFFAOYSA-N 9-propyl-3h-purine-2,6-dione Chemical compound N1C(=O)NC(=O)C2=C1N(CCC)C=N2 FDBKULMUJDBIFZ-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 1
- 102400001282 Atrial natriuretic peptide Human genes 0.000 description 1
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 240000001548 Camellia japonica Species 0.000 description 1
- 206010007747 Cataract congenital Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 241000723377 Coffea Species 0.000 description 1
- 235000007460 Coffea arabica Nutrition 0.000 description 1
- 235000010205 Cola acuminata Nutrition 0.000 description 1
- 206010069153 Congenital myopia Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000208150 Geraniaceae Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 108091008585 IP3 receptors Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000007640 Inositol 1,4,5-Trisphosphate Receptors Human genes 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 241001534756 Mungos Species 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- GIYXAJPCNFJEHY-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine hydrochloride (1:1) Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 GIYXAJPCNFJEHY-UHFFFAOYSA-N 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000906034 Orthops Species 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241001119526 Paullinia Species 0.000 description 1
- 235000010242 Paullinia Nutrition 0.000 description 1
- 240000003444 Paullinia cupana Species 0.000 description 1
- 235000000556 Paullinia cupana Nutrition 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 208000029091 Refraction disease Diseases 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical class O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000004447 accommodation reflex Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229940097832 acetazolamide 500 mg Drugs 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000296 active ion transport Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001299 aldehydes Chemical group 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 description 1
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 230000004430 ametropia Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- GOOXRYWLNNXLFL-UHFFFAOYSA-H azane oxygen(2-) ruthenium(3+) ruthenium(4+) hexachloride Chemical compound N.N.N.N.N.N.N.N.N.N.N.N.N.N.[O--].[O--].[Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Ru+3].[Ru+3].[Ru+4] GOOXRYWLNNXLFL-UHFFFAOYSA-H 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000010352 biotechnological method Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 229940085891 caffeine 100 mg Drugs 0.000 description 1
- 229940026310 caffeine 50 mg Drugs 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 235000018597 common camellia Nutrition 0.000 description 1
- 230000004364 congenital myopia Effects 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229940109295 cyclogyl Drugs 0.000 description 1
- SKYSRIRYMSLOIN-UHFFFAOYSA-N cyclopentolate Chemical group C1CCCC1(O)C(C(=O)OCCN(C)C)C1=CC=CC=C1 SKYSRIRYMSLOIN-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 230000004340 degenerative myopia Effects 0.000 description 1
- 208000001309 degenerative myopia Diseases 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000020278 hot chocolate Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 125000002960 margaryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000001196 nonadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229940117953 phenylisothiocyanate Drugs 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 229930002161 purine alkaloid Natural products 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000001725 pyrenyl group Chemical group 0.000 description 1
- 239000005297 pyrex Substances 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 208000014733 refractive error Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- ZIWSGMLADZIGQA-ZXIKQHSJSA-N tyr-somatostatin-28 Chemical compound C([C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CSSC1)C(O)=O)[C@@H](C)O)[C@@H](C)O)=O)C1=CC=C(O)C=C1 ZIWSGMLADZIGQA-ZXIKQHSJSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000012711 vitamin K3 Nutrition 0.000 description 1
- 239000011652 vitamin K3 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
Definitions
- Hypermetropia is caused by the length of the eye being too short in relation to the optical strength of the cornea and the lens. Hypermetropia usually prevails at birth and is normally recorded at the age of 3-5 years. Subsequently it will reduce in proportion with the growth of the eye until the age of 12, from which age it will remain constant for the rest of the persons life.
- One of the methods for identification of effective substances according to the present invention is related to the fact that, developementwise, the retinal pigment epithelium is a part of the retina and forms an electrochemically active cell layer which is located between the choroid membrane of the eye and the neuronal part of the retina (neuroretina). It forms an electrically tight barrier and due to active ion transport (based on the Na + -K + pump) it creates a difference in potential (the standing potential), the cornea-fundal potential, between the inner and the outer part of the eye of approximately 5 Mv.
- the effect of different drugs on [ 3 H]-ryanodine binding can be used to screen for drugs that either strengthens the scleral connective tissue (increases the content of proteoglycans in sclera), or weakens it (decreases the content of proteoglycanes in sclera).
- substances having an effect on the content of proteoglycanes in the scleral tissue may be used for the treatment or prevention of disease relating to the longitudinal growth of the eye.
- fibroblasts in cell cultures may react to physiological electrical fields by taking on an oblong shape and orienting itself with the longitudinal axis orthogonally with the direction of the field (Erickson, C. A, et al., Cell Biol, Vol. 98, January 1984, 296-307). It has also been demonstrated that the connective tissue substance which is produced by fibroblasts may be determined by the shape of the cell (Evangilisti, R. et al, Eur. J. Histochem., 37, 161-172, 1993).
- the present invention relates to a method for identification of substances which have an effect, either inhibiting or increasing, on the longitudinal growth of the human eye.
- This effect may be measured by different methods.
- One of these methods relates to the activation of the Ca 2+ -release channel.
- This Ca 2+ -release channel may be influenced by different effectors on receptors on the cell membrane. Examples of such receptors are the ryanodine receptor (RyR) and the inositol triphosphate (IP 3 ) receptor.
- RyR ryanodine receptor
- IP 3 inositol triphosphate
- Substances increasing the standing potential or c-wave will inhibit the longitudinal growth of the eye and will thus be applicable for treatment of myopia. Substances reducing the standing potential or c-wave will increase the longitudinal growth of the eye and will thus be applicable for treatment of hypermetropia.
- the effect on the composition of the proteoglycanes and/or the collagen specific amino acid present in the connective tissue of the sclera of the eye is due to an influence on the metabolical activity in the retinal pigment epithelium of the substance of the eye.
- the present invention in a still other aspect relates to the use of substances wherein the effect on the pigment epithelium is primarily on the ion exchange over the cell membrane.
- This effect may be regarded as a metabolic effect.
- the method is for screening substances effective of treating disorders of the eye related to the axial length of the eye and comprises identifying substances having an effect substantially on the pigment epithelium compared to the effect on the neuroretina.
- This method may in one embodiment be by treating an animal with the substance and measuring the effect on the composition of the connective tissue of the sclera.
- the method according to the invention also comprises identifying substances effective of inhibiting the longitudinal growth of the eye. These substances are such substances which increase the content of proteglycanes of the sclera, and may be used for the treatment or prevention myopia.
- any substance may be subjected to the method according to the invention.
- Xanthines which is substituted in one or more of position 1, 3, and 7 (of the general formula of xanthine shown i FIG. 3) with any of the following substituents: hydroxy, halogen, triflourmethyl, lower alkyl (C 1-6 ), tertiary amino/alkoxy are preferred for the treatment or prevention of myopia.
- Example 4 shows that the caffeine metabolite theophylline (1,3-dimethylxanthine) partly reduces c-wave at ERG and the standing potential of the eye, and partly reduces the content of proteoglycanes in sclera.
- Theophylline does increase the content of the collagen specific amino acids hydroxyproline and proline, but it reduces the content of hydroxylysine. In total theophylline therefore has an inhibiting effect on the content of connective tissue components and thus a directly opposite effect as compared to the closely familiar substance caffeine.
- Caffeine is transformed,after administration partly to theophylline which works against the stimulatingeffect of caffeine on the scleral tissue. In order to avoid this weakening effect those metabolites can be employed for caffeine which is not transformed into theophylline.
- xanthines which can be effective for treatment of myopia can involve derivatives of xanthine having substituents in other positions than the 7-position.
- xanthines derivatives not having a methyl group in the 7-position may be useful for the treatment of hypermetropia.
- Caffeine is a well-known, component of e.g. coffee, tea, chocolate and cola soft drinks.
- One cup of coffee contains 100-150 mg of caffeine, one cup of tea approximately 60 mg, one cup of cocoa approximately 5 mg, and one glass of cola approximately 20 mg. Only a very small part of the caffeine in cola comes from the cola nut, primarily it is a matter of added caffeine. Thus it has been calculated that the total consumption of caffeine in cola in the U.S.A. corresponds to the amount deriving by way of decaffeinating coffee in the country (James, J. E.: Caffeine and Health, Academic Press, 1991).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention relates to a method for identification of substances which are applicable for treatment or prevention of an insufficient longitudinal growth of the eye (hypermetropia) or for treatment or prevention of an excessive longitudinal growth of the eye (myopia); substances identified by the method for treating or preventing conditions related to the longitudinal growth of the eye; substances and mixtures of substances for the preparation of a pharmaceutical composition for the treatment or prevention of abnormal growth of the axial length of the eye. The identification involves measuring the effect of the substances on the retinal pigment epithelium of the eye, e.g. by detecting the metabolic effect of the substance on the retinal epithelium, the effect on the standing potential or the effect on the proteoglycanes of the scleral tissue of the eye, by way of EOG examination, by way on the size of the so-called c-wave in ERG-recordings, or by the state of the Ca2+-channels or on the [3H]-ryanodine receptors of the retinal pigment epithelium.
Description
- The invention relates to a method for identification of substances which are applicable for treatment or prevention of an insufficient longitudinal growth of the eye (hypermetropia) or for treatment or prevention of an excessive longitudinal growth of the eye (myopia); substances identified by the method for treating or preventing conditions related to the longitudinal growth of the eye; substances and mixtures of substances for the preparation of a pharmaceutical composition for the treatment or prevention of abnormal growth of the axial length of the eye.
- Myopia is caused by the length of the eye being too big in relation to the optical strength of the cornea and the lens so that the picture of a distant object is focused in a point in front of the retina, whereas the picture produced on the retina will be blurred. In other words, myopia is caused by an anomaly between the length of the eye (the axial length) and the refraction in the cornea and the lens.
- The longitudinal growth of the eye (from approximately 17 mm at birth to approximately 24 mm) during the childhood is caused by expansion of the eye content and thus stretching the immature connective tissue in the sclera of the eye which adjusts to the new size of the eye. Normally the eye will reach its permanent length at the age of 12, at which time the connective tissue in the sclera reaches an appropriate degree of maturity and the longitudinal growth of the eye will stop.
- In myopic persons the longitudinal growth of the eye is too high and the longitudinal growth of the eye continues for a longer period of time than in normal individuals.
- Hypermetropia is caused by the length of the eye being too short in relation to the optical strength of the cornea and the lens. Hypermetropia usually prevails at birth and is normally recorded at the age of 3-5 years. Subsequently it will reduce in proportion with the growth of the eye until the age of 12, from which age it will remain constant for the rest of the persons life.
- Approximately 25% of the population are myopic. In some myopic persons the axial length is normal (physiological myopia of <−4 dioptry), in other parsons, the axial length grow is from the age of 8-10 unproportionally much until the approximate age of 20, and subsequently the axial length and thus the myopia are stable (intermediary myopia, glass strength of from approximately −4 to −8 dioptries).
- Finally, in rare cases a continuously growing axial length throughout the entire life can be seen, often connected with bulges in weak areas of the eye wall (scleraectasies). Here the myopia can reach extreme levels for glass strengths of up to approximately −40 dioptries (Excessive/pathological myopia).
- The intermediary form,and the excessive one in particular, is connected to a high risk of severe sight threatening complications such as e.g. retinal detachment, degenerative changes in the yellow spot of the eye (macula degeneration) and glaucoma.
- In the Western part of the world, severe myopia is among the most important causes of blindness.
- The group of myopic persons with a glass strength of more than −6, which comprises parts of the intermediary group and the entire excessive group, comprises approximately 2% of the population, e.g. in Denmark approximately 100 000 persons (Curtin, B. J.: The myopys: Basic science and clinical management, Harper and Row, Philadelphia, (1985)).
- The cause of axial length conditional myopia is unknown.
- It is however known that the longitudinal growth of the eye can be increased by disturbance of the image formation on the retina, eg. experimentally by sewing together the eye lids of test animals (visual deprivation) (Yinon, U., Current Eye Research, vol. 3, 4, 677-690, 1984).
- Administration of dopaminergic substances (apomorphine) in test animals expose visual deprivation inhibits the development of myopia. (Iuvone, P. M., Invest. Ophthalmol. Vis. Sci., 32, 1674-77 (1991)).
- U.S. Pat. No. 5,055,302, Laties and Stone, shows a method for control of abnormal postnatal growth of the eye of an animal with the application of vasoactive intestinal peptide (VIP), PH1 or analogues of such peptides. Such peptides were found to restrain the axial longitudinal growth of a myopic eye.
- U.S. Pat. No. 5,122,522, Laties and Stone, shows a method for control of abnormal postnatal growth of the eye of an animal with the application of pirenzepine, an anticholinergic substance (M1 Muscarine antagonist). The axial longitudinal growth was inhibited by administration of pirenzepine.
- PCT-patent application publication No. WO 94/25034 Laties and Stone, shows a method for control of abnormal postnatal growth of the eye of an animal with the application of tricyclical substances (antidepressiva). The axial longitudinal growth was inhibited by administration of tricyclical substances.
- However, in most cases myopia and hypermetropia are benign conditions which can easily be corrected by means of glasses. In order to justify a medical treatment of these conditions, such treatment must be effective at relatively low dosages and roughly without any side effects, accordingly, as application of VIP, dopaminergic, anticholinergic or tricyclical substances is connected to risk of side effects as, simultaneously, the substances have considerable psychochemical effects these prior art substances are not suitable for such treatment.
- It is also a theory that the growth of the eye can be caused by passive stretching of the scleral connective tissue (Norton, T. T., Invest. Ophthalmol. Vis. Sci., 37(3), S324 (1996), Siegwart, Jr., J. T., Invest. Ophthalmol. Vis. Sci., 37(3), S324 (1996)). Thus it is been shown possible to trigger irreversible stretching of the sclera in young rabbits by increasing the intraoccular pressure but it is not possible to stretch the sclera in mature rabbits (Greene, P. R., ARVO Abstracts, 1978, p. 297). However, tests with reduction of the intraoccular pressure by means of beta-blocking eye drops in humans developing myopia have no effect (Jensen, H., Acta Ophthalmol., Suppl. 200, 69 (1991)).
- There is no model for animal experiments which precisely corresponds to the human conditions. As mentioned above, it is possible to provoke myopia in some animals, e.g. cats and chicken, by sewing together the eye lids of newborn animals, but partly this experimental myopia develops much more rapidly than in humans, and partly the biological age of the animal (newborn) does not correspond to the same age when the myopia typically occurs in human (8-12 years). Furthermore, in chicken the sclera is considerably anomalous as it partly consists of cartilage.
- As the conditions of the eye related to the refractory system is extremely common and preventive treatment is to be applied to children, probably during years of treatment, effective substances should be very safe. Accordingly, it would be a considerable improvement if a method for identification of a number of substances having an effect on the longitudinal growth of the eye was available. Among substances such identified, it would subsequently be possible to select appropriate substances characterized by high efficiency and few side effects.
- The present invention is related to methods for identification of substances or groups of substances being candidates for the treatment or prevention of disease of the eye related to the longitudinal growth of the eye.
- One of the methods for identification of effective substances according to the present invention is related to the fact that, developementwise, the retinal pigment epithelium is a part of the retina and forms an electrochemically active cell layer which is located between the choroid membrane of the eye and the neuronal part of the retina (neuroretina). It forms an electrically tight barrier and due to active ion transport (based on the Na+-K+pump) it creates a difference in potential (the standing potential), the cornea-fundal potential, between the inner and the outer part of the eye of approximately 5 Mv.
- Due to the anatomical conditions of the eye, this electrical field is in the nature of a dipole with+at the cornea and−at the back pole of the eye. The size and changes of the standing potential can thus be estimated with electrodes placed on each side of the eye by means of sideway movements of the eye. (EOG examination (electroocculography which is well known in the art).
- The standing potential is furthermore positively correlated with the size of the so-called c-wave in ERG-recording. (electroretinography, which is well known in the art). According to one aspect of the present invention, the growth of the eye is related to the size and changes of the standing potential of the retinal pigment epithelium of the eye.
- The transepithelial potential of the retinal pigment epithelium is maintained by a difference in ionic concentration between the cytoplasm of the pigment epithelial cell and the internal and external surface. The state of the Ca2+-channels determines intracellular Ca2+. According to one aspect of the present invention, it is believed that substances affecting the state of Ca2+ simultaneously affect the standing potential created by the retinal pigment epithelium. The state of the Ca2+-channels may be determined by [3H] ryanodine binding as the plant alkaloid ryanodine has been extensively used to study the functional interaction of the Ca2+-release channel (Meissner G: Ryanodine receptor/Ca2+ release channels and their regulation by endogenous effectors, Annu Rev Physiol 1994;56:485-508).
- Accordingly, in a further aspect of the invention, the effect of different drugs on [3H]-ryanodine binding can be used to screen for drugs that either strengthens the scleral connective tissue (increases the content of proteoglycans in sclera), or weakens it (decreases the content of proteoglycanes in sclera).
- According to a still further theory behind the present invention, the biomechanical strength of the tissue is believed to be decisive for the stretching of the sclera rather than a change of the intraoccular pressure as described in the prior art above. Substances increasing or decreasing the strength of the scleral tissue may be used according to the present invention for the treatment or prevention of disease relating to the longitudinal growth of the eye. In a further aspect, substances having a substantially selective effect on the posterior part of the sclera is preferred.
- In a still further aspect of the present invention, substances having an effect on the content of proteoglycanes in the scleral tissue may be used for the treatment or prevention of disease relating to the longitudinal growth of the eye.
- Connective tissue such as eg. sclera mainly consists of scattered cells in a base substance of proteoglycanes (proteins added to glycosaminoglycanes (branched polysaccharides)) and collagen fibres. The biomechanical properties of the tissue are determined by the content of these components and their organisation (Scott, J. E., Dermatan Sulphate Proteoglycans, Portland Press, 1993).
- Furthermore, it has been demonstrated that fibroblasts in cell cultures may react to physiological electrical fields by taking on an oblong shape and orienting itself with the longitudinal axis orthogonally with the direction of the field (Erickson, C. A, et al., Cell Biol, Vol. 98, January 1984, 296-307). It has also been demonstrated that the connective tissue substance which is produced by fibroblasts may be determined by the shape of the cell (Evangilisti, R. et al, Eur. J. Histochem., 37, 161-172, 1993).
- The present invention relates to a method for identification of substances which have an effect, either inhibiting or increasing, on the longitudinal growth of the human eye.
- In another aspect, the invention relates to a method for treating and/or preventing myopia and hypermetropia and to pharmaceutical compositions for such treatment, as well as for use of substances for the preparation of medicaments useful for such treatment or prevention.
- According to the present invention it is presumed that some these substances act mainly on the retinal pigment epithelium and in addition on the receptors of the neuroretina.
- In accordance with the present invention it is however believed, that the substances in tha last end excerts the treating or preventing effect through an effect on the ion transport in and out of the cell in the retinal pigment epithelium and thereby exerts its effect on the longitudinal growth of the eye.
- In one aspect the invention comprises screening of an optional number of substances for the effect on the metabolical activity in the retinal pigment epithelium of the eye.
- This effect may be measured by different methods. One of these methods relates to the activation of the Ca2+-release channel. This Ca2+-release channel may be influenced by different effectors on receptors on the cell membrane. Examples of such receptors are the ryanodine receptor (RyR) and the inositol triphosphate (IP3) receptor.
- In another aspect, the present invention relates to the surprising finding that substances affecting the size of the standing potential are useful for the treatment or prevention of abnormal growth of the axial length of the eye.
- Accordingly, by measuring of effect of the substances on the electrochemical potential over the retinal pigment epithelium, the so-called “standing potential”, or the effect on the so-called “c-wave” by electro retinography (ERG), suitable substances for treating or preventing conditions related to the longitudinal growth of the eye are easily identified.
- Substances increasing the standing potential or c-wave will inhibit the longitudinal growth of the eye and will thus be applicable for treatment of myopia. Substances reducing the standing potential or c-wave will increase the longitudinal growth of the eye and will thus be applicable for treatment of hypermetropia.
- In a further aspect of the invention it is believed that physiological electrical fields are important in relation to the extracellular matrix of the scleral tissue and thereby to the biomechanical properties of sclera. An increase of the electrical field is believed to influence the connective tissue cells in the sclera to take on an oblong form and deposit orthogonally on the field, i.e. in the longitudinal direction of the sclera, making the tissue organise more appropriately as concerns content of base substance and packing of collagen fibres. After long time treatment the sclera will be more resistant to draft and thus less likely to give in to the intraoccular pressure, thus avoiding development of myopia.
- In a further aspect of the invention, substances affecting the composition of the proteoglycanes may be used for the treatment of abnormalities of the longitudinal growth of the eye.
- In a further aspect, the invention comprises a method involving analysis of sclera tests from test animals after treatment (0-6 months) with substances influencing the sclera. Accordingly, the method comprises identifying one or more of the following elements: the effect of the substance on the proteoglycanes; the distribution between various glycosaminoglycane types; and the content of collagen specific amino acids. The analysis may additionally comprise identifying the density of collagen fibrils and the distribution between various fibrils diameters by means of electron microscopy.
- According to the present invention, it is possible that the effect on the composition of the proteoglycanes and/or the collagen specific amino acid present in the connective tissue of the sclera of the eye is due to an influence on the metabolical activity in the retinal pigment epithelium of the substance of the eye.
- Substances increasing the content of proteoglycanes and collagen specific amino acids will strengthen the connective tissue in the sclera, reduce the longitudinal growth of the eye and thus work against myopia. Substances increasing the content of dermatane sulphate in proportion to the other glycosaminoglycanes will furthermore strengthen the connective tissue in the sclera and work-against myopia. Substances increasing the density of collagen fibrils and increasing the diameter of the fibrils will furthermore strengthen the connective tissue in the sclera and work against myopia.
- Substances reducing the content of proteoglycanes and collagen specific amino acids will weaken the connective tissue in the sclera, increase the longitudinal growth of the eye and thus work against hypermetropia. Substances reducing the content of dermatane sulphate in proportion to the other glycosaminoglycanes will weaken the connective tissue in the sclera and work against hypermetropia. Substances reducing the density of collagen fibrils and reducing the diameter of the fibrils will furthermore weaken the connective tissue in the sclera and work against hypermetropia.
- In a further aspect, the invention relates to a method for identifying substances affecting the composition of the proteoglycanes of the sclera of the eye, and thereby exert an effect of the strength of the connective tissue.
- FIG. 1 shows the inhibiting effect of a combination of caffeine and L-cystine on the longitudinal growth of the human eye.
- FIG. 2 shows an example of an analysis curve for amino acids by the application of HPLC.
- FIG. 3 shows the general formula of xanthine and of three derivatives thereof, caffeine, theophylline and theobromine, respectively. As appears from the figure, caffeine and theobromine are substituted in
position 7 by a methyl group. - FIG. 4 shows the content of hydroxyproline in anterior and posterior sclera after treatment with the substances described in Example 2.
- FIG. 5 shows the content of hydroxylysine in anterior and posterior sclera after treatment with the substances described in Example 2.
- FIG. 6 shows the content of proline in anterior and posterior sclera after treatment with the substances described in Example 2.
- FIG. 7 shows the content of proteoglycanes in anterior and posterior sclera after treatment with the substances described in Example 2.
- FIG. 8 shows the content of hydroxyproline in anterior and posterior sclera after treatment with the substances described in Example 4.
- FIG. 9 shows the content of hydroxylysine in anterior and posterior sclera after treatment with the substances described in Example 4.
- FIG. 10 shows the content of proline in anterior and posterior sclera after treatment with the substances described in Example 4.
- FIG. 11 shows the content of proteoglycanes in anterior and posterior sclera after treatment with the substances described in Example 4.
- FIG. 12 shows the correlation between the effect of different methylxanthines on the content of proteoglycanes in posterior sclera and the effect of the same methylxanthines on[3H] ryanodine binding capacity compared to that of the control, xanthine. The values appears from Table 13. Caffeine is represented by 1,7-dimethylxanthine since this is the most dominating metabolite in serum of rabbits after feeding with caffeine. As appears from the figure, a 3H ryanodine binding exceeding 130% compared to xanthine seems to be needed to produce a positive effect on the content of proteoglycanes in sclera.
- Interesting embodiments of the aspects of the invention appear from the appended claims.
- The present invention applies the surprising finding that substances which have an increasing effect on the standing potential or c-wave of the eye by ERG will increase the scleral connective tissues ability to resist abnormal growth or stretching, and thus work against development of myopia. The increased resistant may according to the present invention be due to increase in the content of proteoglycanes and/or collagen specific amino acids such as hydroxyproline, hydroxylysine and proline. Furthermore, an increase in the diameter of the collagen fibrils may also contribute to the effect according to the invention.
- It is furthermore believed that the specific glycosaminoglycanes of the proteoglycanes may have an effect on the structure so that an increased proportion of e.g the content of dermatane sulphate in percentages is related to increased mechanical strength of the sclera and thus also work against development of myopia. Similarly, a decrease works against development of hypermetropia
- In a further embodiment, the invention applies the surprising finding that substances which reduce the standing potential or c-wave of the eye by ERG will, in similarity, reduce the content of proteoglycanes and/or collagen specific amino acids, reduce the content of dermatane sulphate in percentages, reduce the diameter of the collagen fibrils, and thus reduce the scleral connective tissues ability to resist stretching, and thus reduce the level of hypermetropia.
- In order to examine whether a substance is able to produce a change in the connective tissue substance of the sclera, it is normally necessary to treat test animals for a long time, presumably several months. Therefore it would be very resource consuming to test a large number of substances by means of this method alone. By confining oneself to testing substances which influence the standing potential or c-wave of the eye by ERG, it becomes much more likely to identify substances which with few or no side effects are able to influence the scleral connective tissue and thus be applicable for treatment of myopia or hypermetropia.
- As will be described in the following, the invention further relates to the surprising finding, that substances effecting the metabolic state of the cells of the retinal pigment epithelium are also able to induce the effects described above. This effect may by detected in different ways, such as by the state of the Ca2+-channels. In addition, the state of the Ca2+-channels may be determined by 3H ryanodine binding, or in another preferred embodiment of the present invention, by the inositol triphosphate (IP3) receptor. Inositol triphosphate increase intracellular calcium.
- Accordingly, substances binding to the receptors and thereby results in an increase in the intracellular calcium ions may be utilized for the treatment of myopia, and substances which inhibit the receptors may be used in the treatment of hypermetropia in accordance with the teaching of the present invention.
- The method according to the invention for screening substances effective of treating disorders of the eye related to the axial length of the eye comprises identifying substances having an effect on the retinal pigment epithelium. It is believed that substances having an effect on the more primitive pigment epithelium and a rather limited effect on neural tissue will result in a treatment having less side effects compared to the use of substances having a substantial effect on the central nervous system.
- Accordingly, the present invention in a still other aspect relates to the use of substances wherein the effect on the pigment epithelium is primarily on the ion exchange over the cell membrane. This effect may be regarded as a metabolic effect. Accordingly, in a further aspect of the invention, the method is for screening substances effective of treating disorders of the eye related to the axial length of the eye and comprises identifying substances having an effect substantially on the pigment epithelium compared to the effect on the neuroretina.
- The present invention relates in its broad definition to a method for screening substances effective of treating disorders of the eye related to the axial length of the eye. The method essentially comprises the identification of substances having an effect on the retinal pigment epithelium of the eye as this effect on the retinal pigment epithelium has a clear connection to the function of the control of the axial growth of the eye.
- As the function of the retinal pigment epithelium is possibly also affected by a direct or receptor effect on neuroretina, the effect on the retinal pigment epithelium may be through an effect of the substance on the neuroretina. In a further aspect of the invention, the substance may have an effect directly on the neuroretina together with a direct effect on the retinal pigment epithelium. In a further aspect the effect on the neuroretina also induces an effect on the retinal pigment epithelium.
- The ion exchange pumping on the cell membrane is driven by cAMP. An effect of a substance to be screened may exert an inhibiting or increasing effect on the pump and thereby on the function of the retinal-epithelium. In other words it could be expressed by the fact that the substances to be screened are selected by the metabolic effect of the substance on the pigment epithelium.
- One preferred method according to the invention is to identify the effect on the pigment epithelium by means of the standing potential and/or on the c-wave by electro retinography (ERG). In a further aspect, also the effect on the a-wave and/or on the b-wave in the neuroretina is measured whereby it is possible to identify substances having an effect substantially on the retinal pigment epithelium compared to an effect on the neuroretina where the latter is shown as an effect on the a-wave and/or on the b-wave.
- In order to identify substances effective of inhibiting the longitudinal growth of the eye, substances increasing the standing potential and/or the c-wave are selected. These substances may be used for the treatment or prevention of myopia.
- In order to identify substances effective of increasing the longitudinal growth of the eye, substances decreasing the standing potential and/or the c-wave are identified. These substances may be used for the treatment or prevention of hypermetropia.
- In a further embodiment of the invention a method for screening substances effective of treating disorders of the eye related to the axial length of the is eye disclosed. The method comprises identifying substances having an effect on the composition of the proteoglycanes and/or the collagen specific amino acid present in the connective tissue of the sclera of the eye.
- This method may in one embodiment be by treating an animal with the substance and measuring the effect on the composition of the connective tissue of the sclera.
- In another embodiment the method comprises adding the substance to a tissue culture comprising retinal pigment epithelium and fibroblasts and identify the impact of the substance on the production and composition of the proteoglycanes and/or the collagen specific amino acid produced by the fibroblasts in the tissue culture.
- The method according to the invention also comprises identifying substances effective of inhibiting the longitudinal growth of the eye. These substances are such substances which increase the content of proteglycanes of the sclera, and may be used for the treatment or prevention myopia.
- Accordingly, substances effective of increasing the longitudinal growth of the eye are the substances decreasing the content of proteoglycanes of the sclera. These substances may be used for the treatment or prevention of hypermetropia.
- The effect of the substance on the proteoglycanes can generally be identified within a period from as early as 1 day to about 12 weeks from the start of the treatment. However, normally at least one week of treatment is necessary for having an effect which can be measured with the existing analytical methods.
- To apply an animal model to a human effect, it is generally preferred that the test animal is a mammal. However other animals such as birds and reptiles may employed in the present method.
- As is evident for the above explanation, and due to the surprising finding that an effect on the retinal pigment epithelium may be utilized for treatment of disorders of the axial length of the eye, any substance may be subjected to the method according to the invention.
-
- wherein R1, R3, R7, and R9 are independently selected from the group consisting of hydrogen, optionally substituted C1-20-alkyl, optionally substituted C2-20-alkenyl, optionally substituted C4-20-alkadienyl, optionally substituted C6-20-alkatrienyl, optionally substituted C2-20-alkynyl, optionally substituted C1-20-alkoxycarbonyl, optionally substituted C1-20-alkylcarbonyl, formyl, optionally substituted aryl, optionally substituted aryloxycarbonyl, optionally substituted arylcarbonyl, optionally substituted heteroaryl, optionally substituted heteroaryloxycarbonyl, optionally substituted heteroarylcarbonyl, carbamoyl, mono- and di(C1-20-alkyl)aminocarbonyl, mono- and di(C1-20-alkyl) amino-C1-20-alkyl-aminocarbonyl, and halogen such as fluoro, chloro, bromo-or iodo, and
- R8 is selected from the group consisting of hydrogen, optionally substituted C1-20-alkyl, optionally substituted C2-20-alkenyl, optionally substituted C4-20-alkadienyl, optionally substituted C6-20-alkatrienyl, optionally substituted C2-20-alkynyl, optionally substituted C1-20-alkoxy, optionally substituted C2-20-alkenyloxy, carboxy, hydroxy, optionally substituted C1-20-alkoxycarbonyl, optionally substituted C1-20-alkylcarbonyl, formyl, optionally substituted aryl, optionally substituted aryloxycarbonyl, optionally substituted aryloxy, optionally substituted arylcarbonyl, optionally substituted arylcarbonyl, optionally substituted heteroaryl, optionally substituted heteroaryloxycarbonyl, optionally substituted heteroaryloxy, optionally substituted heteroarylcarbonyl, amino, mono- and di(C1-20-alkyl)amino, carbamoyl, mono- and di(C1-20-alkyl)aminocarbonyl, amino-C1-20-alkylaminocarbonyl, mono- and di(C1-20-alkyl)aminocarbonyl, amino-C1-20-alkylaminocarbonyl, optionally substituted C1-20-alkylcarbonylamino, guanidino, carbamido, optionally substituted C1-20-alkanoyloxy, sulphono, optionally substituted C1-20-alkylsulphonyloxy, nitro, sulphanyl, optionally substituted C1-20-alkylthio, and halogen such as fluoro, chloro, bromo or iodo.
- Preferably, R1, R3, R7, and R9 are independently selected from the group consisting of hydrogen, optionally substituted C1-6-alkyl, optionally substituted C2-6-alkenyl, optionally substituted C2-6-alkynyl, optionally substituted C1-6-alkylcarbonyl, formyl, optionally substituted aryl, optionally substituted arylcarbonyl, optionally substituted heteroaryl, and optionally substituted heteroarylcarbonyl, and
- R8 is selected from the group consisting of hydrogen, optionally substituted C1-6-alkyl, optionally substituted C2-6-alkenyl, optionally substituted C2-6-alkynyl, optionally substituted C1-6-alkoxy, optionally substituted C2-6-alkenyloxy, carboxy, hydroxy, optionally substituted C1-6-alkoxycarbonyl, optionally substituted C1-6-alkylcarbonyl, formyl, optionally substituted aryl, optionally substituted aryloxycarbonyl, optionally substituted aryloxy, optionally substituted arylcarbonyl, optionally substituted arylcarbonyl, optionally substituted heteroaryl, optionally substituted. heterarloxycarbonyl, optionally substituted heteroaryloxy, optionally substituted heteroarylcarbonyl, amino, mono- and di(C1-6-alkyl)amino, carbamoyl, mono- and di(C1-6-alkyl)aminocarbonyl, optionally substituted C1-6-alkylcarbonylamino, guanidino, carbamido, optionally substituted C1-6-alkanoyloxy, sulphono, optionally substituted C1-6-alkylsulphonyloxy, nitro, sulphanyl, optionally substituted C1-6-alkylthio, and halogen such as fluoro, chloro, bromo or iodo.
- In a further embodiment, R1, R3, R7 and R9 are independently select from the group consisting of hydrogen, optionally substituted C1-6-alkyl, optionally substituted C2-6-alkenyl, optionally substituted C2-6-alkynyl, optionally substituted aryl, and
- R8 is selected from the group consisting of hydrogen, optionally substituted C1-6-alkyl, optionally substituted C2-6-alkenyl, optionally substituted C2-6-alkynyl, optionally substituted C1-6-alkoxy, optionally substituted C2-6-alkenyloxy, carboxy, hydroxy, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylcarbonyl, amino, nitro, sulphanyl, and halogen such as fluoro, chloro, bromo or iodo.
- In a further embodiment the invention relates to the screening of a substance selected from the following group of substances selected based on different criteria with respect to inhibiting or stimulating effects known from the litterature. The group comprises prostaglandine and analogues thereof such as F2 alpha analogues including PhXA41, prostaglandin receptor agonists including PGF 2 alpha, 17-phenyl trinor PGE2, and U46619; adenosine A2-receptor agonists such as 5′ (N-ethyl)-carboxamido adenosine, alpha-2D adrenergic receptor agonists and antagonists; alpha-2-adrenergic agonist such as UK-14,304; prostaglandin agonists such as 16-phenoxy-PGF2 alpha, cloprostenol, 17-phenyl-PGF2 alpha, fluprostenol, and PhXA85; insulin; bumetanide, petides such as bradykinin, arginine vasopressin, bombesine, substance P, pituitary adenylate cyclase activating polypeptide, atrial natriuretic peptide, somatostatin analogues such as Tyr11-somatostatin-14, Leu8, D-Trp22, and Tyr25-somatostatin-28; muscarine receptor agonists and antagonists such as the Carbachol (stimulates production of inositolphosphate by way of M3 muscarinic receptors), 4-diphenylacetoxy-N-methylpiperadine methiodide, atropin and pirencepine (blocking the effect); calcitriol recepter agonist and antagonists, acetylcholin (increases introcellular calcium by inositol triphosphate receptors), nonsteroidal antiinflammatory drugs such as niflumic acid; Thapsigargin; A23187; phosphodiesterase inhibitors such as rolipram and zaprinast, 4-chloro-3-ethyl-phenol; Bastidin; Veratridine; estrogens and derivatives thereof; Tamoxifen; and Bay K 8644 (1,4-Dihydro-2,6-dimethyl-5-nitor-4-(2(triflouromethyl)-phenyl)-3-pyridinencarboxylic acid methyl ester.
- Upon screening, substances selected due their ability of treating myopia or hypermetropia based on the criteria defined in the present text may be used for the preparation of a medicament for treating or preventing disorders of the eye related to the axial length of the eye for a method for treating or preventing the disorder by administration of a pharmaceutically effective amount of the substance to an individual in need thereof.
- In a further embodiment, the present invention relates to a method for treating and/or preventing myopia of a human eye comprising administering to an individual in need thereof a therapeutically effective amount of one or more substances selected from caffeine; 1,7-dimethylxanthine (paraxanthine), 7-methylxanthine (heteroxanthine), isobutylmethylxanthine (IBMX) and derivatives; 3-methylxanthine, 1-methylxanthine, 1-Hexyl-3,7-dimethylxanthine (pentifylline); 1,7-Dimethyl-xanthine; 1,3-Dipropyl-7-methyl-xanthine; 7-Propylxanthine; 7β-Chloroethyl -1,3-dimethylxanthine; 3,7-Dimethyl-1-propargyl-xanthine; 3-Propylxanthine; 1-(5-Oxohexyl)-3,7-dimethylxanthine (pentoxyfylline); 3-Isobutyl-1-methylxanthine; 3,9-Dimethylxanthine 8-Cyclopentyl-1,3-dimethylxanthine; 1,3-Bis(3-methylbut-2-butenyl-7-methylxanthine; 3,7-Dihydro-7-methyl-1,3-dipropyl-1H-purine-2,6-dione; 7-Methyl-1,3-diprenylxanthine(7-methyl-1,3-dipropyl-xanthine; 7-Ethoxyznethyl-1-(5-hydroxy-5-methylhex-methylxanthine (Torbafylline, “HWA 448”); 1-(5 hydoxy-5-methylhexyl)-3-methyl-7-propylxanthine (A 80.2715); 3,7-Dimethyl-1-(5-oxyhexyl)-xanthine (Pentoxifylline, “Trental”);3,7-Dimethyl-1-(5-hydroxyhexyl)-xanthine (Hydroxypentoxifylline); 1-Hexyl-3,7-dimethylxanthine (Pentifylline, “Cosaldon”); 3,7-Dimethyl-1-proparglyxanthine (DMPX); (E)-8-(3,4-Dimethoxystyryl)-1,3-dipropyl-7-methylxanthine (KF 17837) (Lisofylline); 1-(5-Hydroxy-5-methylhexyl)-3-methylxanthine (Albifylline, “HWA 138”): 3-Methyl-1-(5′-oxohexyl)-7-propylxanthine (Propentofylline, “HWA 285”); 1-(5-Hydroxyhexyl)-3,7-dimethylxanthine (BL 194); (E)-1,3-dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine (KF 17.837); 1,3-di-n-butyl-7-(2′oxopropyl)-xanthine (Denbufylline); 1-n-butyl-3-n-propylxanthine (XT-044); 7-(2,3-dihydroxypropyl)-theophylline (Dyphylline); 7-Methyl-8-(2-hydroxy-N-methylethylamino)-theophylline (Cafaminol); 7-(1,3-Dioxolan 2-ylmethyl)-theophylline (Doxofylline); 7-(2-Hydroxyethyl)-1,3-dimethyixanthine (Etofylline); 7-(2-Hydroxypropyl)-1,3-dimethylxanthine (Proxyphylline); Pyridoxine-O-(theophyllin-7-ylethyl)sulphate (Pyridofylline); 7-(2-(3-diethylcarbamoylpropionyloxy)ethyl)-theophylline (Suxamidofylline); Piperazine bis (theophyllin-7-ylacetate)(Acepifylline); 8-benzyl-7-(2-(N-ethyl-N-2-hy-droxyethylamino)ethyl)theophylline (Bamifylline); 2-amino-2-methylpropan-1-ol theophyllinate (Bufylline); 7-(2,3-Dihydroxypropyl)-1,3-dimethylxanthine (Diprophylline); 7-(2-diethylamoinoethyl) 1,3-dimethylxanthine camphor 10 sulphonate (Etamiphylline Camsylate); 3-Propylxanthine (Enprofylline); 4-amino-8-chloro-1-phenyl-(1,2,4)-triazolo (4,3-a)quinoxaline (CP 66713); cysteine/cystine; glycine, forskoline; alpha-2-adrenergic agonist such as brimonidine (UK-14,304), clonidine, apraclonidine, dapiprazole, moxonidine (4-chloro-N-(4,5 dihydro-1H-imidasol-2yl)-6-methoxy-2-methyl-5-pyridinamine), medetomidine, oxymetazoline, or derivatives thereof; peptides such as bradykinin, arginine vasopressin including V2 agonists, bombesine, substance P, pituitary adenylate cyclase activating polypeptide; somatostatin analogues such as Tyr11-somatostatin-14, Leu8, D-Trp22, and Tyr-somatostatin-28 including agonists of somatostatin sst2 receptors, neuropeptide Y including agonists of Y2 receptors, and anlogues of these peptides; calcitriol or analogues of calcitriol or Vitamin D; muscarine receptor agonists such as the Carbachol, acetylincholine or analogues thereof; nonsteroidal antiinflammatory drugs such as niflumic acid; prostaglandine and analogues thereof such as F2 alpha analogues including PhXA41 (latanoprost), prostaglandin receptor agonists including PGF 2 alpha, 17-phenyl trinor PGE2, and U46619 FP, EP1, and TP receptor agonists), UF 021, 16-phenoxy-PGF2 alpha, cloprostenol, 17-phenyl-PGF2 alpha, fluprostenol, and PhXA85; Thapsigargin, A23187, Phosphodiesterase inhibitors including rolipram and Zaprinast, 4-chloro-3-ethylphenol and Bastidin, veratridine, esterogens including analogues thereof; Bay K 8644 (1,4-Dihydro-2,6-dimethyl-5-nitor-4-(2(triflouromethyl)-phenyl)-3-pyridinencarboxylic acid methyl ester; angiotensin converting enzyme inhibitors, in particular captopril (SQ 14225); adenosine A2-receptor agonists such as 5′ (N-ethyl)-carboxamido adenosine and 8-phenylaminoadenosine (CV-1808); Candoxatril (neutral endopeptidase 24.11 (NEP) inhibitor); Met-enkephalin, alphaendorphin or derivatives; and mixtures thereof.
- L-cystine is a sulphurous amino acid which is a component of proteins, e.g. collagen, where the above sulphurous cross-links derive from it. The L-cystine is thus contained in ordinary food.
- In a preferred embodiment, the method comprises use of a mixture of two or more substances having an additive effect on the myopia. In a preferred embodiment, the mixture has a synergistic effect. Both the additive effect and the synergistic effect may by measured by means of the methods described herein, such as by ERG.
- In a still further embodiment, the present invention relates to methods for treating and/or preventing hypermetropia of a human eye comprising treatment by means of therapeutically effective amounts of one or more substances selected from theophylline, xanthine, 1,9-dimethylxanthine; 1,3-Dipropyl-8-(2-(5,6-epoxynorbonyl)-xanthine; 8-Cyclopentyl-1,3-dipropylxanthine (CPDPX); 8-Sulphophenyltheophylline; 1,3-Dipropyl-8-(4-acrylate)phenylxanthine (BW-A1433); (1-Propyl-11C)8-dicyclo-propylmethyl-1,3-dipropylxanthine (11C)KF15372 and 11C-ethyl and 11C-methyl derivatives thereof; 8-Benzyl-7, (2-(ethyl(2-hydroxyethyl)amino)ethyl)theophylline (Bamiphylline); 8-Cyclopentyl-3-(3-((4-(flourosulfonyl)benzoyl)oxyl)prd-pyl)-1-propylxanthine; 1,3-Dipropyl-8-(4-((2-aminoethyl)amino)carbonylmethyl-oxyphenyl)xanthine; 8-(3-chlorostyryl)caffeine; 8-cyclopentyltheophylline; 8-(noradamantan-3 yl)-1,3-dipropylxanthine (KW-3902); 1,3-Dipropyl-8-(3-noradamantyl)-xanthine; 1,3-Dipropyl-8-(4-sulphophenyl)-xanthine; 1,3-Dipropyl-8-(2-amino-4-chlorophenyl)-xanthine; 7β-Hydroxyethyl-1,3-dimethylxanthine; 7-(2,3-Dihydroxypropyl)-1,3-dimethylxanthine; 8-Chloro-1,3-dimethyixanthine; 1,3,9-Trimethylxanthine; 8-Propionic acid-1,3-dimethylxanthine; 7,9-Dimethylxanthine; 8-Phenyl-1,3-dimethylxanthine; 7-Acetic acid-1,3-dimethylxanthine; 9-Propylxanthine; 9-Methylxanthine; 8-Methylxanthine; 8-(p-Sulfophenyl)-1,3-dimethylxanthine; 1,9-Dimethylxanthine; hypoxanthine; fluoxetine; L-ornithine; azetazolamide; bumetanide; Tamoxifen and other estrogen antagonists, the calmodulin antagonist J8, calcium antagonists including nimodipine and nicardipine, Endothelin agonist, in particular sarafotoxin S6c (selective ETB receptor agonist); Dorzolamide (MK-507), sezolamide and MK-927 (thienothiopyran-2-sulfonamide-derivatives carbonic anhydraae inhibitors), methazolamide, ethoxzolamide, leuenkephalin or dervatives; and mixtures thereof.
- In a preferred embodiment, the method comprises use of a mixture of two or more substances having an additive effect on the hypermetropia. In a still more preferred embodiment, the mixture has a synergistic effect. Both the additive effect and the synergistic effect may by measured by means of the methods described herein, such as by ERG.
- Use of a mixture may also be preferred when minor total dosages of each of the substances are preferred compared to a higher total dosage of only one substance.
- The active substance or mixture of substances according to the invention may be administered orally, parenterally, transdermally or transmucosally e.g. as an intranasal formulation or as eyedrops. In addition, a local application in the eye may result in a substantial local concentration of the substance in the retinal area due to the anatomical circumstances of the eye whereby a less systemic effect is achieved. This is e.g. the fact where the substance is applied topically to the eye and where the drainage of the substance is by the uveoscleral pathway.
- The pharmaceutical composition according to the invention comprising the active substance or mixture of substances may be administered in the form of a pharmaceutical composition which is a tablet, a capsule, a sustained release capsule comprising micro capsules of the active ingredient, a solution or suspension, a device for transdermal application, or a suppository or implant, or in any other conventional formulation.
- As the treatment or prevention of abnormal growth of the eye is a longterm treatment to children, the active substance or mixture of substances may be incorporated into a general daily vitamin tablet or be incorporated into foodstuff, so-called functional foods, including softdrinks, milk, bread, etc.
- It is also an aspect of the present invention, that the individual substances may be interchanged during a treatment period, or that one substance is administered in an individual dosage, e.g in the morning, and another substance is administered in the evening.
- In a further aspect of the invention the active ingredient is derived from the biological natural sources. Several methylxanthines naturally occurs in plants. More than 60 plant species throughout the world have been identified as containing 1,3,7-trimethylxanthine, 1,7-dimethylxanthine, 1,3-dimethylxanthine, 1-methylxanthine, 3-methylxanthine, or 7-methylxanthine. These plants includes the species coffea, camellia, cola, paullinia (guarana), iles (maté), theobroma, citrus, geraniaceae, copermecia, phaseolul, mungo, soya bean, beta vulgaris, sugar cane, and xanthophycae. Since the active substances often represents different steps in the synthesis or degradation of more complex methylxanthines, several xanthines may be present in the same plant in concentrations that variate with the season of the year.
- Harvesting the plant at different periods of the season, and using different extraction methods will result in extracts containing high concentration of certain methylxanthines with only minor contributions of other, and less desired methylxanthines. In a further embodiment of the invention, a extraction method is described that results in a composition rich in 7-methylxanthine, taking advantage of the fact that 7-methylxanthines is more easily dissolved than the other methylxanthines.
- Other embodiments relates to extraction of beta vulgaris, sugar canes, xanthophycae and other plants comprising 7-methylxanthines.
- Depending on the exact dissolving properties of the desired active ingredient, the extraction method may be adapted for the specific plant as well as for the desired active ingredient.
- Examples of a suitable extraction method is given below in Examples 6 and 7.
- In a still other aspect, the active ingredient for treating or preventing disease of the longitudinal growth of the eye may be produced by genetic engineering such as by transgenic plants expressing the active ingredient or by other biotechnological methods.
- In addition to genetic manipulation, the plant material, for the purpose of increasing the yield of certain methylxanthines from the plant material, the plant may be subjected to treatment with substances that block or facilitate certain enzymes that determines the metabolism of the metylxanthines. As an example of this, treatment of coffee plants with allopurinol will result in accumulation of great amounts of 7-methylxanthine in the plant (Ashihara H (1996). Catabolism of caffeine and related purine alkaloids i leaves of coffea arabica; L. Planta 1998:334-339)
- Registration of c-Wave at ERG in animals (e.g. rabbits) is a well-developed examination technique (Skoog, K. O., Nilsson, S. E. G., Acta Ophthalmol. (Kph), 52: 759-773 (1974), Jarkman, S., Skoog, K. O., Doc. Ophthalmol., 60: 383-392 (1985)). Also intraoccular administration of test substances for test animals is also a well-described technique (Textorius, O., Doc. Ophthalmol., 63:349-358 (1986)). Alternatively, test substances can be administered intravenously (Jarkman, S., Doc. Ophthalmol. 60: 375-382 (1985)).
- In addition, it is possible to determine the effect of test substances on the standing potential and c-wave at ERG indirectly by means of an in-vitro arrangement with a retinal pigment epithelium-choroidea preparation, and to determine the transepithelial potential (Kawasaki, K., Doc. Ophthalmol., 63: 375-381 (1986))
- By means of such examination techniques which can facilitate quick examinations it is according to the present invention possible to examine a large number of substances in various concentrations and to determine which substances have a strong effect on the activity of the pigment epithelium of the retina.
- Determination of the content of proteoglycanes in tissue samples can be performed by means of several well-developed methods (eg. Björnsson, S., Analytical Biochemistry 210, 282-291 (1993)).
- The content of the collagen specific amino acids (hydroxyproline, hydroxylysine, and proline) can be determined eg. by means of autoanalysis (Blumenkrantz, N., Clin. Biochem. 13: 177-183 (1980)) or by means of high pressure liquid chromatography (HPLC) or other methods. A method for determination of the content of collagen specific amino acids in connective tissue by means of application of HPLC has been described in detail below.
- A method for determination of the content of dermatane sulphate in percentages in relation to the other glycosaminoglycanes (cellulose acetate electroforese) has been described in detail below.
- The following Table 1 shows a-number of specific preferred xanthine substances according to the present invention effective for treating and/or preventing myopia, and in Table 2 for hypermetropia.
TABLE 1 Substances effective for treating and/or preventing myopia 1. 1,3-Bis(3-methylbut-2-butenyl-7- methylxanthine 2. 3,7-Dihydro-7-methyl-1,3-dipropyl-1H-purine-2,6- dione 3. 7-Methyl-1,3-diprenylxanthine(7-methyl-1,3-dipropyl- xanthine 14. 7-Ethoxymethyl-1-(5-hydroxy-5-methylhexyl)3- methylxanthine (Torbafylline, “HWA 448”) 5. 1-(5 hydoxy-5-methylhexyl)-3-methyl-7-propylxanthine (A 80.2715) 6. 3,7-Dimethyl-1-(5-oxyhexyl)-xanthine (Pentoxifylline, “Trental”) 7. 3,7-Dimethyl-1-(5-hydroxyhexyl)-xanthine (Hydroxypentoxifylline) 8. 1-Hexyl-3,7-dimethylxanthine (Pentifylline, “Cosaldon”) 9. 3,7-Dimethyl-1-proparglyxanthine (DMPX)2) 10. (E)-8-(3,4-Dimethoxystyryl)-1,3-dipropyl-7-methylxanthine (KF 17837) (Lisofylline) 11. 1-(5-Hydroxy-5-methylhexyl)-3-methylxanthine (Albifylline, “HWA 138”) 12. 3-Methyl-1-(5′-oxohexyl)-7-propylxanthine (Propentofylline, “HWA 285”) 13. 1-(5-Hydroxyhexyl)-3,7-dimethylxanthine (BL 194) 14. (E)-1,3-dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine (KF 17.837)1) 15. 1,3-di-n-butyl-7-(2′oxopropyl)-xanthine (Denbufylline) 16. 1-n-butyl-3-n-propylxanthine (XT-044) 17. 7-(2,3-dihydroxypropyl)-theophylline (Dyphylline) 18. 7-Methyl-8-(2-hydroxy-N-methylethylamino)-theophylline (Cafaminol) 19. 7-(1,3-Dioxolan 2-ylmethyl)-theophylline (Doxofylline) 20. 7-(2-Hydroxyethyl)-1,3-dimethylxanithine (Etofylline) 21. 7-(2-Hydroxypropyl)-1,3-dimethylxanthine (Proxyphylline) 22. Pyridoxine-O-(theophyllin-7-ylethyl)sulphate (Pyridofylline) 23. 7-(2-(3-diethylcarbamoylpropionyloxy)ethyl)theophylline (Suxamidofylline) 24. Piperazine bis(theophyllin-7-ylacetate) (Acepifylline) 25. 8-benzyl-7-(2-(N-ethyl-N-2-hydroxyethylamino)ethyl)theo- phylline (Bamifylline) 26. 2-amino-2-methylpropan-1-ol theophyllinate (Bufylline) 27. 7-(2,3-Dihydroxypropyl)-1,3-dimethylxanthine Diprophylline) 28. 7-(2-diethylamoinoethyl)-1,3- dimethylxanthine camphor 10sulphonate (Etamiphylline Camsylate) 29. 3-Propylxanthine (Enprofylline) 30. 4-amino-8-chloro-1-phenyl-(1,2,4)-triazolo(4,3- a)quinoxaline (CP 71366)1) -
TABLE 2 Substances effective for treating and preventing of hypermetropia 31. 1,3-Dipropyl-8-(2-(5,6-epoxynorbonyl)- xanthine 3)32. 8-Cyclopentyl-1,3-dipropylxanthine (CPDPX)4) 33. 8-Sulphophenyltheophylline 34. 1,3-Dipropyl-8-(4-acrylate)phenylxanthine (BW-A1433)5) 35. (1-Propyl-11C) 8-dicyclopropylmethyl-1,3-dipropylxanthine (11C) KF15372 and 11C-ethyl and 11C-methyl derivatives thereof All4) 36. 8-Benzyl-7,(2-(ethyl(2-hydroxyethyl)amino)ethyl)theo- phylline (Bamiphylline) 37. 8-Cyclopentyl-3-(3-((4-(flourosulfonyl)benzyl)oxyl)Pro- pyl)-1- propylxanthine 3)38. 1,3-Dipropyl-8-(4-((2-aminoethyl)amino)carbonylmethyl- oxyphenyl)xanthine 39. 8-(3-chlorostyryl) caffeine 40. 8-cyclopentyltheophylline3) 41. 8-(noradamantan-3 yl)-1,3-dipropylxanthine (KW-3902) 42. 1,3-Dipropyl-8-(3-noradamantyl)-xanthine3) 43. 1,3-Dipropyl-8-(4-sulphophenyl)- xanthine 44. 1,3-Dipropyl-8-(2-amino-4-chlorophenyl)-xanthine 45. Hypoxanthine -
TABLE 3 Effect of xanthines on [3H] ryanodine binding to skeletal RyR Bound [3H] ryanodine, % of control +3 mmol/l +1 mmol/l AMP AMPPCP Control (-xanthine) 100 100 100 1-Hexyl-3,7-dimethylxanthine 549 ± 33* 449 ± 28* 414 ± 47* (pentifylline) 1,7-Dimethyl- 240 ± 27* 378 ± 34* 360 ± 28* xanthine 1,3-Dipropyl-7-methyl- 220 ± 23* 326 ± 30* 295 ± 23* xanthine 7-Propylxanthine 216 ± 25* 234 ± 14* 270 ± 12* 7β-Chloroethyl-1,3-dimethyl- 220 ± 27* 256 ± 34* 230 ± 9* xanthine 3,7-Dimethyl-1-propargyl- 193 ± 15* 201 ± 33* 230 ± 6* xanthine 3-Propylxanthine 211 ± 13* 203 ± 14* 226 ± 14* 7-Methylxanthine 204 ± 25* 214 ± 15* 225 ± 11* 1-(5-Oxohexyl)-3,7-dimethyl- 187 ± 16* 185 ± 25* 188 ± 5* xanthine (pentoxyfylline) 1,3,7-Trimethylxanthine 155 ± 22* 164 ± 11* 182 ± 18* (caffeine) 1-Methylxanthine 153 ± 15* 167 ± 16* 179 ± 22* 3-Isobutyl-1-methyl- 137 ± 16* 139 ± 11* 175 ± 20* xanthine 1,3-Dimethylxanthine 136 ± 29* 148 ± 8* 170 ± 25* (theophylline) 3,7-Dimethylxanthine 124 ± 22* 136 ± 8* 160 ± 22* (theobromine) 3,9-Dimethyl- 146 ± 26* 141 ± 11* 143 ± 20* xanthine 3-Methylxanthine 155 ± 24* 137 ± 10* 134 ± 9* 8-Cyclopentyl-1,3-dimethyl- 155 ± 24* 142 ± 14* 133 ± 6* xanthine 7β-Hydroxyethyl-1-1,3-dimethyl- 113 ± 13* 134 ± 15* 124 ± 15* xanthine 7-(2,3-Dihydroxypropyl)-1,3-di- 100 ± 16 123 ± 16* 117 ± 9* methylxanthine 8-Chloro-1,3-dimethyl- 98 ± 25 108 ± 14 116 ± 17 xanthine 1,3,9-Trimethyl- 103 ± 18 103 ± 15 105 ± 7 xanthine 8-Propionic acid-1,3-dimethyl- 113 ± 13 100 ± 11 102 ± 5 xanthine 7,9-Dimethyl- 99 ± 14 100 ± 15 102 ± 13 xanthine 8-Phenyl-1,3-dimethyl- 109 ± 11 103 ± 14 99 ± 18 xanthine 7-Acetic acid-1,3-dimethyl- 93 ± 15 99 ± 12 98 ± 19 xanthine 9-Propylxanthine 102 ± 24 97 ± 23 96 ± 12 9-Methylxanthine 96 ± 11 85 ± 18 98 ± 10 8-Methylxanthine 109 ± 9 90 ± 11 95 ± 20 8-(p-Sulfophenyl)-1,3-di- 95 ± 7 91 ± 16 92 ± 17 methylxanthine 1,9-Dimethyl- 76 ± 13 86 ± 18 84 ± 14 xanthine - (Specific [3H]ryanodine binding was determined as described in Materials and Methods in Liu et AL.,Structure-activity Relationship of Xanthines and Skeletal Muscle Ryanodine Receptor/Ca2+ Release Channel; Pharmacology1997;54:135-143. Xanthine concentrations were 1.5 mmol/l. Control [3H]ryanodine binding values (-xanthines) were 0.55±0.05, 0.73±0.08 and 1.69±0.12 pmol/mg protein in the absence and presence of 3 mmol/l AMP or 1 mmol/l AMPPCP, respectively. * Significantly different from control at p<0.05.)
- From the above Table 3 it is seen that nonpolar residues in positions, 1, 3 and 7 stimulated [3H] ryanodine binding, whereas nonpolar residues in positions 8 and 9 counteracted the effect.
- According to the present invention, substances which have an effect on the [3H] ryanodine binding of at least 130%, preferable more than 150% of that of the control xanthine are effective for treating or preventing disease related to excessive longitudinal growth of the eye, and substances which have an effect on the [3H] ryanodine binding of less than 130%, preferable less than 100% of that of the control. xanthine are effective for treating or preventing disease of insufficient longitudinal growth of the eye.
- According to the present invention, the substances disclosed in Table 3 having the highest binding effect are most preferred for treating of myopia, such as the substance showing an effect on the [3H] ryanodine binding of more than 200% compared to the control xanthine, and includes the substance Pentifylline. The substances disclosed in Table 3 having the lowest indingeffetare mst preferred for treating of hypermetropia, such as the substance showing an effect on the [3H] ryanodine binding of less than 110% compared to the control xanthine, and includes the
substance 1,9-dimethylxanthine.TABLE 4 Effect of xanthines on [3H] ryanodine binding to skeletal RyR in the presence of 1 mmol/1 AMPPCP Bound [3H] ryanodine pmol/mg % of protein control Monosubstituted xanthines Control (-xanthine) 1.69 ± 0.12 100 7-Propyl- 4.57 ± 0.20 270 ± 12* 3-Propyl- 3.82 ± 0.23 226 ± 14* 7-Methyl- 3.80 ± 0.19 225 ± 11 1-Methyl- 3.02 ± 0.38 179 ± 22* 3-Methyl- 2.26 ± 0.15 134 ± 9* 9-Propyl- 1.62 ± 0.20 96 ± 12 9-Methyl- 1.66 ± 0.17 98 ± 10 8-Methyl- 1.61 ± 0.33 95 ± 20 Disubstituted xanthines Control (-xanthine) 1.69 ± 0.12 100 1,7-Dimethyl- 6.08 ± 0.47 360 ± 28* 3-Butyl-1-methylxanthine 2.96 ± 0.33 175 ± 20* 1,3-Dimethyl- 2.87 ± 0.42 170 ± 25* (theophylline) 3,7-Dimethyl-(theobromine) 2.70 ± 0.37 160 ± 22* 3,9-Dimethyl- 2.42 ± 0.34 143 ± 20* 7,9-Dimethyl- 1.73 ± 0.22 102 ± 13 1,9-Dimethyl- 1.42 ± 0.23 84 ± 14 1-Substituted 3,7-dimethylxanthines 3,7-Dimethyl- 2.70 ± 0.37 100 xanthine (control) 1-Hexyl-(pentifylline) 6.99 ± 0.80 259 ± 24* 1-Propargyl- 3.88 ± 0.10 144 ± 3* 1-(5-Oxohexyl)-(pentoxyfylline) 3.18 ± 0.08 118 ± 3* 1-Methyl-(caffeine) 3.07 ± 0.30 114 ± 2 7-Substituted 1,3-dimethylxanthines 1,3-Dimethyl- 2.87 ± 0.42 100 xanthine (control) 7β-Chloroethyl- 3.88 ± 0.16 135 ± 6* 7-Methyl-(caffeine) 3.07 ± 0.301 107 ± 4 7β-Hydroxyethyl- 2.10 ± 0.26 73 ± 4* 7-(2,3-Dihydroxypropyl)- 1.97 ± 0.16 69 ± 6* 7-Acetic acid- 1.65 ± 0.32 57 ± 6* 8-Substituted 1,3-dimethylxanthines 1,3 Dimethyl- 2.87 ± 0.42 100 xanthine(control) 8-Cyclopentyl- 2.25 ± 0.28 78 ± 8 8-Chloro- 1.96 ± 0.13 68 ± 4* 8-Propionic acid- 1.73 ± 0.09 60 ± 3* 8-Phenyl- 1.67 ± 0.31 58 ± 9* 8-(p-Sulfophenyl)- 1.55 ± 0.28 54 ± 6* Others 1,3-Dipropyl-7-methyl- 4.96 ± 0.39 xanthine 1,3,9-Trimethylxanthine 1.77 ± 0.12 - ([3H]ryanodine-binding measurements were determined as described in Materials and Methods in Liu et AL.,Structure-activity Relationship of Xanthines and Skeletal Muscle Ryanodine Receptor/Ca2+Release Channel; Pharmacology, 1997;54:135-143. Xanthine concentrations were 1.5 mmol/l. The control bound [3H]ryanodine for each subgroup was set equal to 100. Results are means±SD of 3-4 separate experiments. * Significantly different from controls at p<0.05.)
- From this Table 4, the effect of the individual substituents to the xanthine molecule structure is clearly demonstrated.
- Xanthines which is substituted in one or more of
position - On the other hand, when the xanthine is substituted in one or more of position 8 and 9 with these substituents, the substance is useful for treatment or prevention of hypermetropia, especially if the xanthine is only substituted in these positions.
- When the xanthine is substituted in both
positions 7 and 9, such as in 7,9-Dimethylxanthine, the double bond between the nitrogen atom and carbon atom as shown in the general formula (I) is hydrogenated as appears from formula III. - In the present context, the term “C1-20-alkyl” is intended to mean a linear, cyclic or branched hydrocarbon group having 1 to 20 carbon atoms, such as methyl, ethyl, propyl, iso-propyl, cyclopropyl, butyl, tert-butyl, iso-butyl, cyclobutyl, pentyl, cyclopentyl, hexyl, cyclohexyl, hexadecyl, heptadecyl, octadecyl, nonadecyl. Analogously, the term “C1-6-alkyl” is intended to mean a linear, cyclic or branched hydrocarbon group having 1 to 6 carbon atoms, such as methyl, ethyl, propyl, iso-propyl, pentyl, cyclopentyl, hexyl, cyclohexyl.
- Preferred examples of “C1-6-alkyl” are methyl, ethyl, propyl, iso-propyl, butyl, tert-butyl, iso-butyl, pentyl, cyclopentyl, hexyl, cyclohexyl, in particular methyl, ethyl, propyl, iso-propyl, tert-butyl, iso-butyl and cyclohexyl.
- Similarly, the terms “C2-20-alkenyl”, “C4-20-alkadienyl”, and “C6-20-alkatrienyl” are intended to mean a linear, cyclic or branched hydrocarbon group having 2 to 20, 4 to 20, and 6 to 20, carbon atoms, respectively, and comprising one, two, and three unsaturated bonds, respectively. Analogously, the term “C2-6-alkenyl” is intended to mean a linear, cyclic or branched hydrocarbon groups having 2 to 6 carbon atoms and comprising one double bond.
- Examples of alkenyl groups are vinyl, allyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, heptadecaenyl. Examples of alkadienyl groups are butadienyl, pentadienyl, hexadienyl, heptadienyl, heptadecadienyl. Examples of alkatrienyl groups are hexatrienyl, heptatrienyl, octatrienyl, and heptadecatrienyl.
- The term “C2-20-alkynyl” is intended to mean a linear or branched hydrocarbon group having 2 to 20 carbon atoms and comprising a triple bond. Examples hereof are ethynyl, propynyl, butynyl, octynyl, and dodecaynyl. Analogously, the term “C2-6-alkynyl” is intended to mean a linear or branched hydrocarbon groups having 2 to 6 carbon atoms and comprising one triple bond, such as ethynyl, propynyl, butynyl, pentynyl, and hexynyl.
- In the present context the term “alkoxy” means alkyl-oxy, and “halogen” means fluoro, chloro, bromo, iodo.
- In the present context, i.e. in connection with the terms “alkyl ”, “alkenyl”, “alkadienyl”, “alkatrienyl”, “alkynyl”, and “alk{overscore (o)}xy”, the term “optionally substituted” is intended. to mean that the group in question may be substituted one or several times, preferably 1-3 times, with group(s) selected from hydroxy (which when bound to an unsaturated carbon atom may be present in the tautomeric keto form), C1-6-alkoxy (i.e. alkyl-oxy), C2-6-alkenyloxy, carboxy, oxo (forming a keto or aldehyde functionality), C1-6-alkoxycarbonyl, C1-6-alkylcarbonyl, formyl, aryl, aryloxycarbonyl, aryloxy, arylcarbonyl, heteroaryl, heteroaryloxycarbonyl, heteroaryloxy, heteroarylcarbonyl, amino, mono- and di(C1-6-alkyl)amino; carbamoyl, mono- and di-(C1-6-alkyl)aminocarbonyl, amino-C1-6-alkyl-aminocarbonyl, mono- and di(C1-6-alkyl)amino-C1-6-alkyl-aminocarbonyl, C1-6-alkylcarbonylamino, guanidino, carbamido, C1-6-alkanoyloxy, sulphono, C1-6-alkylsulphonyloxy, nitro, sulphanyl, C1-6-alkylthio, trihalogen-C1-6-alkyl, halogen such as fluoro, chloro, bromo or iodo, where aryl and heteroaryl may be substituted as specifically described below for “optionally substituted aryl and heteroaryl”.
- In the present context the term “aryl” is intended to mean a fully or partially arormatic carbocyclic ring or ring system, such as phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, anthracyl, phenanthracyl, pyrenyl,-benzopyrenyl, fluorenyl and xanthenyl, among which phenyl is a preferred example.
- The term “heteroaryl” is intended to mean a fully or partially aromatic carbocyclic ring or ring system where one or more of the carbon atoms have been replaced with heteroatoms, e.g. nitrogen, sulphur, and/or oxygen atoms. Examples of such heteroaryl groups are oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrrolyl, imidazolyl, pyrazolyl, pyridinyl, pyrazinyl, pyridazinyl, piperidinyl, coumaryl, furyl, quinolyl, benzothiazolyl, benzotriazolyl, benzodiazolyl, benzooxozolyl, phthalazinyl, phthalanyl, triazolyl, tetrazolyl, isoquinolyl, acridinyl, carbazolyi, dibenzazepinyl, indolyl, benzopyrazolyl, phenoxazonyl. Preferred hete.roaryl groups are pyridinyl, benzopyrazolyl, and imidazolyl.
- In the present context, i.e. in connection with the terms “aryl” and “heteroaryl”, the term “optionally substituted” is intended to mean that the group in question may be substituted one or several times, preferably 1-5 times, in particular 1-3 times) with group(s) selected from hydroxy (which when present in an enol system may be represented in the tautomeric keto form), C1-6-alkyl, C1-6-alkoxy, oxo (which may be represented in the tautomeric enol form), carboxy, C1-6-alkoxycarbonyl, C1-6-alkylcarbonyl, formyl, aryl, aryloxy, aryloxycarbonyl, arylcarbonyl, heteroaryl, amino, mono- and di(C1-6-alkyl)amino; carbamoyl, mono- and di(C1-6-alkyl)amino-carbonyl, amino-C1-6-alkyl-anocarbonyl, mono- and-di(C1-6-alkyl)amino-C1-6-alkyl-aminocarbonyl, C1-6-alkylcarbonylamino, guanidino, carbamido, C1-6-alkanoyloxy, sulphono, C1-6-alkyl-sulphonyloxy, nitro, sulphanyl, dihalogen-C1l4-alkyl, -trihalogen-C1-6-alkyl, halogen such as fluoro, chloro, bromo or iodo, where aryl and heteroaryl representing substituents may be. Preferred examples are hydroxy, C1-6-alkyl, C1-6-alkoxy, carboxy, C1-6-alkoxycarbonyl, C1-6-alkylcarbonyl, aryl, amino, mono- and di(C1-6-alkyl)amino, and halogen such as fluoro, chloro, bromo or iodo, wherein aryl and heteroaryl may be substituted as above.
- The pharmaceutical preparation according to the present invention may be formulated in accordance with conventional pharmaceutical practice with pharmaceutical excipients conventionally used for the preparation of oral, topical and systemical formulations. In addition, many of the substances are well known medical formulations.
- The concentration of the substance or mixture of substances may be present in the medicament in an amount of 0.001-99%, typically 0.01-75%, more typically 0.1-20%, especially 1-10% by weight of the medicament, however, for many of the substances are already avaible for pharmaceutical use, and generally, the substances are then to be used in ordinary clinical dosageg and concentrations known in the litterature.
- In another aspect of the invention, the dosage is correlated to an effect similar to the eeffect of the testes drugs of the present invention and which appears from the examples. This correlation may be performed by the measuring methods as described en the present text.
- The preparation of the invention may also contain other additives such as emulsifieres, stabilizing agents, preservatives, etc.
- The invention is furthermore described in the claims and rendered probable in the following examples.
- List of Examples
- Example 1 Materials and Methods
- Example 2 Biochemical changes in rabbit sclera after long term treatment with Fluoxetine, Teofylamin, Caffeine and L-cysteine.
- Example 3 Effect of myopia progression in a human by treat ment with caffeine and L-cysteine.
- Example 4 Biochemical changes in rabbit sclera after longterm treatment with 7-methylxanthine, Theobromine, Acetazolamide,; and L-ornithine.
- Example 5 Effect on proteoglycanes compared with effect on [3H] ryanodine binding of different xanthines.
- Example 6 Extraction method for substance from natural source.
- Example 7 Extraction method for substance from natural source.
- Example 8 Experiments under investigation
- Comments to the Examples
- On the basis of the biochemical results in Example 2 it is likely that a treatment of myopia with caffeine will be more efficient than L-cystine as a moderate dosage of caffeine unambiguously affects all parameters appropriately.
- In humans caffeine has a relatively long half-life period (approximately 5 hours). After administration of a dosage of caffeine, the serum concentration of caffeine is therefore dominant, however, with an essential contribution of the pharmacologically
active metabolites 1,7-dimethylxanthine (paraxanthine), 3,7-dimethylxanthine (theobromine), and 1,3-dimethylxanthine (theophylline), 1-methylxanthine, 3-methylxanthine, and 7-methylxanthine (heteroxanthine). - In rabbits the half-life period for caffeine is short (approximately 1 hour) and the most essential contribution for the serum comes from
te metabolite 1,7-dimethylxanthine whereas the serum concentration of caffeine will be esbentially lower. - The strong effect of caffeine on the biochemical composition of sclera, as it appears from Example 2, is believed to be due to the above-mentioned metabolites of caffeine.
- Example 3 demonstrates that substances identified according to Example 2 of having specific effects on the biochemical composition of sclera of a non-human mammal, the rabbit, in fact are able to prevent inappropriate growth of the eye, in a human.
- Example 4 shows that the caffeine metabolite theophylline (1,3-dimethylxanthine) partly reduces c-wave at ERG and the standing potential of the eye, and partly reduces the content of proteoglycanes in sclera. Theophylline does increase the content of the collagen specific amino acids hydroxyproline and proline, but it reduces the content of hydroxylysine. In total theophylline therefore has an inhibiting effect on the content of connective tissue components and thus a directly opposite effect as compared to the closely familiar substance caffeine.
- Caffeine is transformed,after administration partly to theophylline which works against the stimulatingeffect of caffeine on the scleral tissue. In order to avoid this weakening effect those metabolites can be employed for caffeine which is not transformed into theophylline.
- Theophylline only differs from caffeine by not having a 7-methyl group. Other appropriate substances for treatment of myopia among caffeine derivatives or analogues with a 7-methyl group include. 1,7-dimethylxanthine (paraxanthine), and 7-methylxanthine (heteroxanthine) are especially interesting, however also 3-methylxanthine and 1-methylxanthine are believed to be effective against myopia.
- Other 7-methyl xanthines which can be effective for treatment of myopia can involve derivatives of xanthine having substituents in other positions than the 7-position. In a similar way, xanthines derivatives not having a methyl group in the 7-position may be useful for the treatment of hypermetropia.
- Materials and Methods
- Test animal: Charles River Deutschland Chinchilla Bastard female rabbits.
- Number of animals: 6 test animals and 6 control animals
- Age: approximately 8 weeks at the commencement of the test.
- Weight: 1.4-1.9 kg at the commencement of the test.
- Lightness/Darkness cycle: 12/12 hours.
- Water: ad libitum.
- Cages: The animals live in identical cages made of stainless steel-(Scanbur), length 1 m, depth 0.52 m, height 0.5 m.
- Food: Stanrab standard diet from Special Diet Services, P.O. Box 705, Witham Essex CM8 3AD, UK (further details, see Table A).
- Amount of food: Increasing from 75 g per day at the commencement of the test up to 130 g after three months.
-
Experimental drinking water 1 contained theophyllin in a dose equivalent of 27 mg increasing to 63 mg (added as theophyllin and ethylendiamin in a dose of 33 to 77 mg) daily. -
Experimental drinking water 2 contained fluoxetine (Fontex, Lilly) in a dose equivalent of 2 mg increasing to 5 mg daily. -
Experimental diet 1 was added caffeine (1,3,7-trimethylxanthine) 500 mg per kg Stanrab standard diet equivalent of a daily caffeine dose of 37.5 g increasing to 65 g per day. -
Experimental diet 2 was added 4.5 g L-cystine per kg Stanrab standard diet equivalent of a daily L-cystine dose of 338 mg increasing to 585 mg per day. With respect to the supplement of L-cystine, the normal intake per day of the standard diet is 218 mg increasing to 377 mg L-cystine. -
Experimental diet 3 was added 7-methylxanthine 500 mg per kg Stanrab standard diet equivalent of a daily 7-methylxanthine dose of 37.5 g increasing to 65 g per day. -
Experimental diet 4 was added theobromine (3,7-dimethylxanthine) 500 mg per kg Stanrab standard diet equivalent of a daily theobromine dose of 37.5 g increasing to 65 g per day. -
Experimental diet 5 was added acetazolamide 500 mg per kg Stanrab standard diet equivalent of a daily acetazolamide dose of 37.5 g increasing to 65 g per day. -
Experimental diet 6 was added 4.5 g L-ornithine per kg Stanrab standard diet equivalent of a daily L-ornithine dose of 338 mg increasing to 585 mg per day. - Collection of sample: Sclera biopsies are taken for analysis for proteoglycane content, distribution between the individual glycosaminoglycanes and the content of collagen specific amino acids. Four tests from each animal: Two samples from the front, 5×10 mm along limbus (without cornea), and two samples from the back, punch 10 mm corresponding to the center of the retina. Furthermore, tests are taken for electron microscopy (EM) from two animals in each group.
- Analyses: Samples for proteoglycane analysis are frozen down immediately. The samples are analyzed by Wieslab AB, IDEON, S-223 70 Lund, Sweden, by means of a method which has been described by Björnsson, S., Analytical Biochemistry 210, 282-291 (1993). The method comprises extraction by 20 microlitres of 4 M guanidine-HCl, 50 Mm sodium acetate per mg wet weight over night by room temperatures. The extracts are centrifuged in order to remove debris. 20 microlitres of supernatant are reduced {fraction (1/10)} in extraction buffer and 20 microlitres of reduced supernatant are mixed with 10 microlitres of reagent 1 (see Björnsson, S., Analytical biochemistry 210, 282-291 (1993)) on a shaking table for 15 minutes. 200 microlitres of
reagent 2 are added and the tests are incubated for 60 minutes in order to precipitate the proteoglycanes. The proteoglycane/alcian blue precipitate is transferred to 96-wells MillBlotD apparatus and washed with 2×200 microlitres of 40% DMSO, 0.05 M of MgCl2. The colour intensity of the wells are quantitated by microtech E3 scanner and Scan Analysis software (Biosoft, Cambridge, U.K.). Chrondroitine-6-sulphate (Sigma C4384) is used as the calibrator. All samples are analyzed in duplicate. - Samples for analysis for content of collagen specific amino acids are frozen down immediately. The amino acid content is determined by HPLC-chromatography. The tissue bits are delipidized with acetone at 4° C. in 3×24 hours, then with acetone:diethylether 1:1 for 24 hours, and finally 1 hour of standing with pure diethylether.
- Then they are dried to constant weight by standing in vacuum exsiccator for 1.5 hours with the pump on and after closure standing over night.
- The dried tissue with constant weight is minced into very fine particles with a pair of scissors, approximately 20 per piece of tissue. The small flakes from each original piece of tissue are divided into two equally sized portions, one of which is employed for hydrolysis and the other one is kept for reference. The constant dry weight of each portion is known.
- The finely divided tissue is hydrolyzed in Pyrex glass tube s for 24 hours at 114° C., and subsequently the hydrolysates are dried (removal of remnants from of hydrochloric acid) by standing in vacuum exsiccator at 40° C. over night. The dry residue of hydrolysate is resolubilized in 320 microliter of 0.1N hydrochloric acid by standing in ultrasound bath for 10 minutes vortexing and then standing over night at 4° C. surrendered by a final wortexing and centrifugation.
- From each
resolubilized hydrolysate 3 aliquots of each 8 microlitres and 3 aliquots of 40 μl are taken and transferred to separate polypropylene tubes in which 20 microlitres of a solution of internal standard substances citrulline and 2 aminobutyric acid were added where the further method takes place. - The taken aliquots from hydrolysate are dried in a vacuum exsiccator at 35° C. over night and subsequently submitted to derivatization with phenylisothiocyanate.
- The resulting phenylisothiocarbamates are transferred to the HPLC instrument for separation and quantification. A new set of calibration curves is established, 1 curve for each of the 19 amino acids, prior to the analysis of the samples from one investigation.
- The concentration range of standard samples exceed the ranges of amino acid concentrations in the unknowns. Hydroxyproline and proline are quantitated from the 8 microliter aliquots, and hydroxylysine is quantitated from the 40 microliter aliquots.
- The curves were straight with a high coefficient of correlation.
- Samples for analysis of the distribution between the various glycosaminoglycanes are immediately put in acetone. The analysis is made with a method described by Olsen, E. B., Acta Orthop. Scand. 60 (1), 23-25 (1989), comprising delipidization, drying, digestion with pronase. The glycosaminoglycanes are seperated in the procedure comprising centyltrimethyl ammonium bromide. The glycosam centyltrimethyl ammonium bromide complex is washed with ethanol saturated with NaCl in order to remove centyltrimethyle ammonium bromide. The cleaned Na-glycosaminoglycanes are dried and resolubilized in NaOH and distilled water for further analysis. The individual glycosaminoglycanes are separated by means of cellulose acetate electroforese, and the relative content of the essential glycosaminoglycanes are measured by means of optical scanning.
- EM is made on ultra thin cuts from the center part of the biopsies after fixation in 4% of glutaraldehyde in caccodylate buffer with 7.5% sucrose at 40° C. over night, dehydrated in ethanol and moulded in epoxy resin. The cuts are stained with saturated uranyl acetate solution in 50% of ethanol for 1 hour, followed by lead citrate (Reynolds) for 3 minutes for routine electron microscopy.
- Ultra thin cuts are collected on gold nets and stained by means of periodine acid-silver proteinate technique for glucoproteins (PAS) and with 0.1% of ruthenium red solution in 0.1 M ammonia for acidic glycosaminoglycanes. The results of longterm treatment with each of the 8 substances specified above are shown in Example 2 (treatment for 12 weeks) and Example 4 (treatment for 10 weeks).
- No significant differences between control and treatment groups was identif ed with respect to bodyweight and weight of eyes.
- Long time treatment of 3 month with each of the four substances, Caffeine, L-cysteine, Teofylamin, and Fluoxetine and the effect on the biochemical changes in rabbit sclera
TABLE 5 Content of collagen specific amino acicis in nanomol/mg tissue (dried weight defatted weight) from anterior sclera (Wilcoxon test. *p < 0.05), and the increase (Inc.) or decrease (Decr.) compared to the control. Hydroxyproline Hydroxylysine Proline Control 604 +/− 50 41 +/− 12 886 +/− 29 Fluoxetine 619 +/− 40 33 +/− 11 896 +/− 21 Teofylamin 653 +/− 39 28 +/− 10 958 +/− 23 Caffeine 688 +/− 36* 39 +/− 19 993 +/− 18* L-cystine 599 +/− 41 45 +/− 10 885 +/− 22 Hydroxyproline Hydroxylysine Proline Inc. Decr. Inc. Decr. Inc. Decr. Fluoxetine — — — 20% — — Teofylamin 8% — — 32% 8% — Caffeine 14% — — — 12% — L-cystine — — — — — — -
TABLE 6 Content of collagen specific amino acids in nanomol/mg tissue (dried weight and defatted weight) from posterior sclera (Wilcoxon test.), and the increase (Inc.) or decrease (Decr.) compared to the control. Hydroxyproline Hydroxylysine Proline Control 547 +/− 141 43 +/− 12 810 +− /86 Fluoxetine 640 +/− 31 41 +/− 13 927 +/− 15 Teofylamin 643 +/− 74 28 +/− 15 902 +/− 53 Caffeine 668 +/− 61 37 +/− 16 947 +/− 38 L-cystine 596 +/− 39 43 +/− 8 867 +/− 14 Hydroxyproline Hydroxylysine Proline Inc. Decr. Inc. Decr. Inc. Decr. Fluoxetine 17% — — — 15% — Teofylamin 18% — — 35% 11% — Caffeine 22% — — 14% 17% — L-cystine 9% — — — 7% — -
TABLE 7 Content of proteoglycanes in μg PG/mg tissue (wet weight) (Wilcoxon test. *p < 0.05), and the increase or decrease compared to the control. Anterior sclera Posterior sclera Control 2.7 +/− 0.2 2.7 +/− 0.2 Fluoxetine 2.2 +/− 0.4* 2.6 +/− 0.2 Teofylamin 2.4 +/− 0.5 2.7 +/− 0.3 Caffeine 3.2 +/− 0.8 3.2 +/− 0.5 L-cystine 3.5 +/− 0.5* 3.5 +/− 0.4* Anterior sclera Posterior sclera Increase Decrease Increase Decrease Fluoxetine — 19% — — Teofylamin — 11% — — Caffeine 19% — 19% — L-Cystine 29% — 29% — - Conclusion:
- Fluoxetine: Treatment with fluoxetine (a serotonin re-uptake inhibitor) for three months decreased the content of proteoglycanes in anterior sclera by 19%. Hydroxylysine in the anterior sclera is decreased with 20% and hydroxyproline and proline are increased with 17% and 15%, respectively, in the posterior sclera.
- Teofylamin: Treatment with Teofylamin for 3 months reduces the content of proteoglycanes in sclera by 11% (at the front).
- Caffeine: Treatment with caffeine for three months increases the content of proteoglycanes in sclera by 19% (to the front) and 19% (to the back). The content of the collagen specific amino acids hydroxyproline and proline are increased by 22% and 17%, respectively, in sclera tests in the back of the eye. Accordingly, the example shows that treatment or a young mammal with caffeine in a moderate dosage results in a strong increase in the content of proteoglycanes as well as in collagen specific amino acids in sclera.
- L-cystine: Treatment of young rabbits for three months with L-cystine increases the content of proteoglycanes in the sclera by 29% in both the front and in the back of eye. The content of the collagen specific amino acids hydroxyproline and proline are increased by 9% and 7%, respectively, in sclera samples from the back of the eye. Accordingly, the example shows that treatment with a relative large dosage of L-cystine also increases the content of proteoglycanes, but that the effect on the content of collagen specific amino acids is ambiguous.
- Myopia progression stopped by treatment with caffeine and L-cystine
- A boy presented with myopia at the age of 9 years. Earlier examination showed no ametropia. He had severely progrediating myopia and was treated with a combination of caffeine (100 mg/day) and L-cystine (200 mg/day) for three months followed by a control period of three months with no treatment, and subsequently a new treatment period followed by a control period, etc. In total 4-treatment periods and 4 control periods alternated.
- Measurement of the axial length of the eye was made by means of Auto Axial Biometer AL-010, Shin-Nippon.
- Table 8 and Table 9 shows the average growth in the axial length of both eyes in the 4 treatment periods and the 4 control periods, respectively.
TABLE 8 Treatment with caffeine 50 mg × 2 and L-cystine 100 mg × 2(tablets) from day 0-90, day 161-289, and 412-570. Day RE LE 0 23.74 23.70 57 23.86 23.58 118 24.06 23.83 161 24.14 24.07 227 24.21 24.03 260 24.26 24.10 289 24.24 24.22 350 24.43 24.44 392 24.56 24.47 412 24.59 24.39 447 24.63 24.53 476 24.73 24.52 503 24.74 24.53 541 24.72 24.49 570 24.71 24.55 -
TABLE 9 Average growth during treatment and control periods, respectively. Axial length growth n Caffeine + L-cysteine 0.089 mm 4 (100 + 200 mg/day) Control period 0.253 mm 4 - Conclusion: Example 3 confirms that treatment with a combination of caffeine and L-cystine actually is able to inhibit the myopia progression in a child as a significant effect of the treatment with a factor of 3 (inhibition of growth) in relation to no treatment is demonstrated in study.
- The Effect of the Caffeine Metabolite 7-methylxanthine (heteroxanthine) 50 mg per Animal Daily on Scleras Content of Proteoglycanes and Collagen Specific Amino Acids
- The effect of the
caffeine metabolite 3,7-dimethylxanthine (theobromine) 50 mg per animal daily on scleras content of proteoglycanes and collagen specific amino acids. - The effect of
acetazolamide 50 mg per animal daily on scleras content of proteoglycanes and collagen specific amino acids. - The effect of 500 mg per animal daily of L-ornithine on scleras content of proteoglycanes and collagen specific amino acids.
- Conclusion: No significant differences were found as regards the content of proteoglycans in the sclera samples, but there was a near significant increase in 7-methylxanthine treated posterior sclera, and a decrease in theobromine treated posterior sclera.
- Significant higher content of all collagen specific amino acids, except hydroxylysine in anterior sciera, was found in all sclera samples from theobromine (3,7-dimethylxanthine) treated animals. Animals treated with 7-methylxanthine showed significantly higher content of hydroxyproline and proline in posterior sclera. Treatment with acetazolamide reduced the content of hydroxyproline and proline in anterior sclera significantly.
TABLE 10 Content of proteoglycanes in μg PG/mg tissue (wet weight) anterior sclera posterior sclera Control 2.9 +/− 0.5 2.9 +/− 0.4 7-methyixanthine 2.5 +/− 0.5 3.3 +/− 0.3 3,7-dimethyixanthine 2.6 +/− 0.7 2.5 +/− 0.4 Acetazolamide 2.9 +/− 0.4 2.8 +/− 0.8 L-ornithine 3.0 +/− 1.1 3.0 +/− 0.9 Anterior sclera Posterior sclera Increase Decrease Increase Decrease 7-methylxanthine — 14% 14% — 3,7-dimethylxanthine — 10% — 14% Acetazolamide — — — — L-ornithine — — — — -
TABLE 11 Content of collagen specific amino acids in nanomol/mg tissue (dried weight defatted weight) from anterior sclera. (Wilcoxon test. *p < 0.05) Hydroxyproline Hydroxylysine Proline Control 638 +/− 24 45 +/− 10 928 +/− 56 7-methylxanthine 667 +/− 73 45 +/− 3 951 +/− 111 3,7-dimethylxanthine 751 +/− 53* 49 +/− 6 1073 +/− 78* Acetazolamide 596 +/− 27* 41 +/− 4 843 +/− 47* L-ornithine 605 +/− 37 37 +/− 4 875 +/− 48 -
TABLE 12 Content of collagen specific amino acids in nanomol/mg tissue dried weight and defatted weight) from posterior sclera. (Wilcoxon test. *p < 0.05) Hydroxyproline Hydroxylysine Proline Control 622 +/− 59 41 +/− 5 864 +/− 67 7-methylxanthine 719 +/− 81* 44 +/− 7 1018 +/− 108* 3,7-dimethylxanth. 741 +/− 18* 49 +/− 4* 1029 +/− 45* Acetazolamide 563 +/− 91 38 +/− 6 781 +/− 125 L-ornithine 611 +/− 24 38 +/− 5 871 +/− 35 Hydroxyproline Hydroxylysine Proline Inc. Decr. Inc. Decr. Inc. Decr. 7-methylxanthine 16% — 7% — 10% — 3,7-dimethylxanth. 19% — 20% — 20% — Acetazolamide — 10% — 7% — 10% L-ornithine — — — 7% — — - Effect on Proteoglycanes Compared with Effect on [3H Ryanodine Binding of Different Xanthines
- Comparison of effect on proteoglycanes content of posterior sclera in % to control with effect on [3H ryanodine binding in % compared to control.
TABLE 13 Effect on proteoglycan Effect on [3H content of posterior ryanodine binding sclera in % in % compared compared to control to control Caffeine 119 240 Theophylline 100 136 7-methylxanthine 114 204 Theobromine 86 124 - Extraction Method
- The plant material must either be extracted immediately after harvesting or stored at −20° C. until extraction take place, and preferable, the material is freeze-dried before the cold storage. The material is finely ground and boiled for 20 minutes with 0.0125 N sulphuric acid. After cooling the extract is applied to a column packed with siliceous earth (Extralut, Merck), 700 p per litre of extract, and after 10 minutes the column is eluted with a 4-fold volume of chloroform. The chloroform phase is eluted to dryness and chloroform condensed and collected for re-use. The residue contains the methylxanthines.
- The plant material must either be extracted immediately after harvesting or stored at −20° C. until extraction can take place, and preferable, the material must be freeze-dried before the cold storage. The material is finely ground and boiled for 20 minutes with =0.1N hydrochloric acid. After cooling the extract is filtered and applied to a column packed with polyvinylpyrrolidone powder, and after 10 minutes the column is eluted with water. The fraction of the eluate which has a high concentration of the methylxanthine in question is collected and evaporated to a standardized concentration of this substance.
- Experiments under investigation:
- A) The effect of the
Caffeine metabolite 3,7-dimethylxanthine (theobromine) on c-wave by ERG and the standing potential of the eye is under investigation. - B) The effect of the caffeine metabolite 7-methylxanthine (heteroxanthine) on c-wave by ERG and the standing potential of the eye is under investigation.
- C) Pilot projects
- Substances to be tested for treatment or preventing of myopia:
- 1) Caffeine and L-cystine (dosages as described)
- 2) 7-methylxanthine 250 mg
- 3) Pentifylline 250 mg Substances to be tested for treatment or preventing of hypermetropia:
- 4) 1,9-dimethylxanthine 250 mg
- 5) theobromine 250 mg (may be used once or twice daily equivalent of 10 or 20 mg per kg per day with a body weight of 25 kg)
- The Test conditions:
- Caffeine and L-cystine are to be given as tablets for the inhibition of the progression of myopia in a group of children aged 10-14.
- The Background of the Test
- The content of L-cystine in the food varies depending on whether the protein need is covered by e.g. fish (approximately 350 mg L-cystine per day for a child weighing 30 kg) or wheat bread (approximately 700 mg L-cystine per day) (Garrow, J. S.: Human Nutrition and Dietetics, Churchill Livingstone, 1993). L-cystine is absorbed through the intestine, the part that is not used for the building up of the proteins of the body is burnt on equal terms with e.g. sugar.
- Caffeine is a well-known, component of e.g. coffee, tea, chocolate and cola soft drinks. One cup of coffee contains 100-150 mg of caffeine, one cup of tea approximately 60 mg, one cup of cocoa approximately 5 mg, and one glass of cola approximately 20 mg. Only a very small part of the caffeine in cola comes from the cola nut, primarily it is a matter of added caffeine. Thus it has been calculated that the total consumption of caffeine in cola in the U.S.A. corresponds to the amount deriving by way of decaffeinating coffee in the country (James, J. E.: Caffeine and Health, Academic Press, 1991).
- From the above foods children in the U.S.A. aged 10-17 consume approximately 1.5 mg of caffeine per kg weight per day, i.e. for a child of 30 kg approximately 45 mg per day (Albeit, M. L.: Journal of the American Dietetic Association, 88, 466-471 (1988). A Finnish examination showed that approximately 40% of children aged 12 consumed one or more cups of coffee per day. An even larger percentage consumed tea or hot chocolate every day (55<, E.: Social Science and Medicine, 26, 259-264 (1988).
- L-cystine is an important factor in the stabilisation of the collagen molecules in the sclera as it forms the basis of sulphurous cross-links. Therefore, it is possible that, in a period with heavy body weight increase, a relative lack of L-cystine can lead to an unstable collagen and thus participate in developing myopia.
- Therefore it is possible that supplementing the diet with L-cystine can inhibit the development of myopia.
- Candidates of substances applicable for treatment of such a relatively benign condition as myopia in so many children must necessarily be free of almost any side effects.
- Caffeine and L-cystine comply with. this condition. Treating a 9-year old boy with severely increasing myopia (Example 3) also implies an effect as the axial longitudinal growth over a period of three months was reduced from 0.253 mm to 0.089 mm with
caffeine 100 mg +L-cystine 200 mg per day. The treatment showed no side effects. - The normal longitudinal growth of the human eye for the age of 3-14 amounts to approximately 0.1 mm per year, but there is much variation. In approximately 15% the axial longitudinal growth is thus >0.4 mm per year (Sorsby, A., Med. Res. Counc. Spec. Rep. Ser., No. 301, London, 1962). Particularly this group develops myopia.
- c. Test persons
- Boys and girls aged 10-14 with progreding myopia.
- Inclusion: 3×12 myopic persons, 10-14 years old, glass strength >−1.25.
- Exclusion: Severe ordinary disease (e.g. asthma, epilepsy, diabetes, physical disease), severe congenital myopia other severe eye diseases (e.g. congenital cataract, ceratoconus, chronic iritis, glaucoma).
- The test persons were recruited from practising ophthalmologists.
- As myopia develops in the childhood it is necessary to apply children in the test.
- e. Method
- Pilot test.
- 12 persons are treated with tablets of caffeine, 50 mg in the morning and 50 mg in the evening for 6 months.
- 12 persons are treated with tablets of L-cystine, 100 mg in the morning and 100 mg in the evening for 6 months.
- 12 persons are treated with tablets of caffeine, 50 mg, and tablets of cystine, 100 mg in the morning and in the evening for 6 months.
- Then a control period of 6 months follows with no treatment. The level of myopia progression for the two periods is compared for each participant.
- Furthermore, the myopia progression in the treatment period is compared with existing material concerning myopia progression in children of the same age group (e.g. Jensen, H.: Myopia progression in young school children, Acta Ophthal., Suppl. 200, Vol 69, 1991).
- During the test the following examinations are made:
- 1. Statup at the commencement of the test.
- a. Subjective measuring of glass strength (ordinary glass determination)
- b. Refraction determination with auto refractor (objective determination of the glass strength) in cyclogylcycloplegy (cancelling the accommodation reflex with cyclogyl drops).
- c. Measuring the axial length with Shin-Nippon axial length measurer. The patient is dripped with local anaesteticum, and an ultra sound probe is put on the eye by means of a tonometer set at 15 mmHg. The axial length is stated in mm by the apparatus by 2 digits.
- Three measurements are made and the average is calculated.
- 2. Measurement of the axial length after two months (as 1c).
- 3. Measurement of the axial length after 4 months (as 1c).
- 4. Status after 6 months (as 1a-c).
- 5. Measurement of the axial length after 8 months (as 1c).
- 6. Measurement of the axial length after 10 months (as 1c).
- 7. Status after 12 months (as 1a-c).
- Data identifying the patient is destroyed at the end of the test.
TABLE A STANDARD RABBIT DIET (STANRAB) Crude Oil % 3.1 Glycine % 1.39 Crude Protein % 16.7 Aspartic acid % 1.14 Crude Fibre % 14.8 Glutainic acid % 3.01 Ash % 8.1 Proline % 1.18 N.F.E. % 47.3 Serine % 0.70 Dig, Crude Oil % 2.8 Hydroxyproline % — Dig, Crude % 14.9 Hydroxylysine % — Protein Tot, Dietary % 31.9 Alanine % 0.11 Fibre Pectin % 2.4 Calcium % 0.83 Hemicellulose % 14.7 Total Phosphorous % 0.61 Cellulose % 11.7 Phytate % 0.36 Phosphorous Lignin % 3.1 Available % 0.25 Phosphorous Starches % 22.7 Sodium % 0.25 Sugars % 7.5 Chlorine % 0.36 Gross Energy mj/k 14.8 Magnesium % 0.41 Dig, Energy mj/k 9.1 Potassium % 1.52 Met, Energy mj/k 8.2 Iron mg/kg 194.0 Myrletoleic % 0.02 Copper mg/kg 17.0 acid Palmitoileic % 0.09 Manganese mg/kg 93.0 acid Oleic acid % 0.79 Zinc mg/kg 47.0 Linoleic acid % 0.75 Cobalt mcg/kg 535.0 Linolenic acid % 0.18 Iodine mcg/kg 665.0 Arachidonic % 0.15 Selenium mcg/kg 217.0 acid Clupanodonic % — Fluorine mg/kg 24.0 acid Lauric acid % 0.03 Retinol mcg/kg 47473.0 Myristic acid % 0.18 Vitamin A iu/kg 156991.0 Palmitic acid % 0.37 Cholecalciferol mcg/kg 37.6 Stearic acid % 0.07 Vitamin D3 iu/kg 1504.0 Arginine % 1.21 α-Tocopherol mg/kg 62.0 Lysine % 0.91 Vitamin E mg/kg 68.2 Methionine % 0.35 Vitamin B1 mg/kg 10.6 Cystine % 0.29 Vitamin B2 mg/kg 14.2 Tryptophan % 0.28 Vitamin B6 mg/kg 7.6 Histidine % 0.44 Vitamin B12 mcg/kg 11.0 Threonine % 0.68 Vitamin C mg/kg 113.0 Isoleucine % 0.74 Vitamin K3 mg/kg 63.2 Leucine % 1.28 Folic acid mg/kg 2.1 Phenylalanine % 0.82 Nicotinic acid mg/kg 73.8 Valine % 0.88 Pantothenic mg/kg 34.7 acid Tyrosine % 0.62 Choline mg/kg 1151.0 Taurine % — Inositol mg/kg 1515.0 Biotin mcg/kg 344.0 p-aminobenzoic mg/kg — acid β-Carotene mg/kg 99.2 Xanthophyl mg/kg —
Claims (72)
1. A method for screening substances effective of treating or preventing disorders of the eye related to the axial length of the eye comprising identifying substances based on an effect by the substance on the retinal pigment epithelium of an eye.
2. The method according to claim 1 further comprising administering the substance to an individual and measuring the effect of the substance on the retinal pigment epithelium of the individual upon administration.
3. The method according to claim 1 comprising administering the substance to an in vitro preparation of retinal pigment epithelium and measuring the effect of the substance on the retinal pigment epithelium therein.
4. The method according to any of claims 1 and 2 wherein the effect on the retinal pigment epithelium is through an effect of the substance on the neuroretina.
5. The method according to any of claims 1 and 2 wherein the substance further has an effect on the neuroretina.
6. The method according to claim 5 wherein the effect on the neuroretina also induces an effect on the retinal pigment epithelium.
7. The method according to any of the preceding claims wherein the effect on the retinal pigment epithelium is on the ion exchange over the cell membrane of the retinal epithelium such as on the Ca2+ exchange, e.g. through the receptors ryanodine receptor (RyR) and/or on the inositol trisphosphate (IP3) receptor.
8. The method according to any of the preceding claims wherein the effect on the retinal pigment epithelium is a metabolic effect.
9. The method according to any of the preceding claims wherein the effect on the retinal pigment epithelium is an effect substantially directly on the retinal pigment epithelium compared to an effect through an effect on the neuroretina.
10. The method according to any of the preceding claims wherein the effect of the substance on the retinal pigment epithelium is measured by means of the standing potential and/or on the amplitude of the c-wave by electro retinography (ERG).
11. The method according to any of claims 9 and 10 wherein the effect on the retinal pigment epithelium is measured by means of the amplitude of the c-wave by electro retinography (ERG) and the effect on the neuroretina is measured by means of the amplitude of the a-wave and/or b-wave by electro retinography (ERG) upon administration of the substance.
12. The method according to any of the preceding claims wherein the substance increases, upon administration or application of the substance, the standing potential and/or the amplitude of the c-wave measured by electro retinography (ERG) and/or increases ryanodine receptor (RyR) and/or inositol trisphosphate (IP3) receptor binding.
13. The method according to claim 12 for identifying substances effective of inhibiting the longtitudinal growth of the eye.
14. The method according to claim 13 for identifying substances for the treatment or prevention of myopia.
15. The method according to any of claims 1-11 wherein the substance decreases, upon administration or application of the substance, the standing potential and/or the amplitude of the c-wave measured by electro retinography (ERG) and/or decreases ryanodine receptor (RyR) and/or inositol trisphosphate (IP3) receptor binding.
16. The method according to claim 15 for identifying substances effective of increasing the longtitudinal growth of the eye.
17. The method according to claim 16 for identifying substance for the treatment of hypermetropia.
18. The method according to any of claims 12 and 15 wherein the increase or decrease, respectively, corresponds to at least 10% compared to the initial value, such as at least 20%, preferable at least 25%.
19. The method according to any of the preceeding claims wherein the substance is a mixture of two or more substances.
20. A method for screening substances effective of preventing or treating disorders of the eye related to the axial length of the eye comprising identifying substances having an effect on the composition of the proteoglycanes and/or the collagen specific amino acid present in the connective tissue of the sclera of the eye.
21. The method according to claim 20 comprising administering the substance to an animal and measuring the effect on the composition of the proteoglycanes and/or the collagen specific amino acid present in the connective tissue of the sclera upon administration.
22. The method according to claim 20 comprising administering the substance to an in vitro preparation of retinal pigment and scleral tissue and measuring the effect of the substance on the composition of the proteoglycanes and/or the collagen specific amino acid present in the tissue culture.
23. The method according to claim 20 comprising adding the substance to a tissue culture comprising fibroblasts and identifying the effect on the composition of the proteoglycanes and/or the collagen specific amino acid produced by the fibroblasts.
24. The method according to any of claims 20-23 wherein the substance increases the content of proteglycanes of the sclera compared to the initial value.
25. The method according to claims 22-24 wherein the substances effective of inhibiting the longtitudinal growth of the eye
26. The method according to claim 25 for identifying substances for the treatment of myopia.
27. The method according to any of claims 20-23 wherein the substance decreases the content of proteglycanes of the sclera, in the tissue culture or in the in vitro preparation, respectively.
28. The method according to claim 27 for identifying substances effective of increasing the longtitudinal growth of the eye.
29. The method according to claim 28 for identifying substances for the treatment of hypermetropia.
30. The method according to any of claims 21-29 wherein the effect of the substance is detectable within a period from about 1 week to about 12 weeks from the start of the treatment.
31. The method according to any of claims 21-30 wherein the animal is a mammal, the tissue culture or the in vitro preparation is derived from an mammal, respectively.
32. The miethod according to any of the preceeding claims wherein the substance is selected from the group consisting of prostaglandine and analogues thereof; and compounds of the general formula I, II or III
wherein R1, R3, R7, and R9 are independently selected from the group consisting of hydrogen, optionally substituted C1-20-alkyl, optionally substituted C2-20-alkenyl, optionally substituted C4-20-alkadienyl, optionally substituted C6-20-alkatrienyl, optionally substituted C2-20-alkynyl, optionally substituted C1-20-alkoxycarbonyl, optionally substituted C1-20-alkylcarbonyl, formyl, optionally substituted aryl, optionally substituted aryloxycarbbnyl, optionally substituted arylcarbonyl, optionally substituted heteroaryl, optionally substituted heteroaryloxycarbonyl, optionally substituted heteroarylcarbonyl, carbamoyl, mono- and di(C1-20-alkyl)aminocarbonyl, mono- and di(C1-20-alkyl)amino-C1-20-alkyl-aminocarbonyl, and halogen such as fluoro, chloro, bromo or iodo, and
R8 is selected from the group consisting of hydrogen, optionally substituted C1-20-alkyl, optionally substituted C2-20-alkenyl, optionally substituted C4-20-alkadienyl optionally substituted C6-20-alkatrienyl, optionally substituted C2-20-alkynyl, optionally substituted C1-20-alkoxy, optionally substituted C2-20-alkenyloxy, carboxy, hydroxy, optionally substituted C1-20-alkoxycarbonyl, optionally substituted C1-20-alkylcarbonyl, formyl, optionally substituted aryl, optionally substituted aryloxycarbonyl, optionally substituted aryloxy, optionally substituted arylcarbonyl, optionally substituted arylcarbonyl, optionally substituted heteroaryl, optionally substituted heteroaryloxycarbonyl, optionally substituted heteroaryloxy, optionally substituted heteroarylcarbonyl, amino, mono- and di(C1-20-alkyl)amino, carbamoyl, mono- and di(C1-20-alkyl)aminocarbonyl, amino-C1-20-aminocarbonyl, mono- and di(C1-20-alkyl)amino-C1-20-alkylaminocarbonyl, optionally substituted C1-20-alkylcarbonylamino, guanidino, carbamido, optionally substituted C1-20-alkanoyloxy, sulphono, optionally substituted C1-20-alkylsulphonyloxy, nitro, sulphanyl, optionally substituted C1 20-alkylthio, and halogen such as fluoro, chloro, bromo or iodo.
33. Method according to claim 32 , wherein R1, R3, R7, and R9 are independently selected from the group consisting of hydrogen, optionally substituted C1-6-alkyl, optionally substituted C2-6-alkenyl, optionally-substituted C2-6-alkynyl, optionally substituted C1-6-alkylcarbonyl, formyl, optionally substituted aryl, optionally substituted arylcarbonyl, optionally substituted heteroaryl, and optionally substituted hetetoarylcarbonyl, and
R8 is selected from the group consisting of hydrogen, optionally substituted C1-6-alkyl, optionally substituted C2-6-alkenyl, optionally substituted C2-6-alkynyl, optionally substituted C1-6-alkoxy, optionally substituted C2-6alkenyloxy, carboxy, hydroxy, optionally substituted C1-6-alkoxycarbonyl, optionally substituted C1-6-alkylcarbonyl, formyl, optionally substituted aryl, optionally substituted aryloxycarbonyl, optionally substituted aryloxy, optionally substituted aryicarbonyl, optionally substituted arylcarbonyl, optionally substituted heteroaryl, optionally substituted heteroaryloxycarbonyl, optionally substituted heteroaryloxy, optionally substituted heteroarylcarbonyl, amino, mono- and di(C1-6-alkyl)amino, carbamoyl, mono- and di(C1-6-alkyl)aminocarbonyl, optionally substituted C1-6-alkylcarbonylamino, guanidino, carbamido, optionally substituted C1-6-alkanoylpxy, sulphono, optionally substituted C1-6-alkylsulphonyloxy, nitro, sulphanyl, optionally substituted C1-6-alkylthio, and halogen such as fluoro, chloro, bromo or iodo.
34. The method according to claim 33 , wherein R1, R3, R7 and R9 are independently selected from the group consisting of hydrogen, optionally substituted C1-6-alkyl, optionally substituted C2-6-alkenyl, optionally substituted C2-6-alkynyl, optionally substituted aryl, and
R8 is selected from the group consisting of hydrogen, optionally substituted C1-6-alkyl, optionally substituted C2-6-alkenyl, optionally substituted C2-6-alkynyl, optionally substituted C1-6-alkoxy, optionally substituted C2-6alkenyloxy, carboxy, hydroxy, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylcarbonyl, amino, nitro, sulphanyl, and halogen such as fluoro, chloro, bromo or iodo.
35. Use of a substance having an effect on the retinal pigment epithelium identified according to the method described in any of the claims 1-34 for the preparation of a medicament for treating or preventing disorders of the eye related to the axial length of the eye.
36. Use according to claim 35 for the preparation of a medicament for topical application in the form of a preparation suitable for application on mucosa e.g. for application on eye mucosa e.g. eye drops, eye salve, eye gel, or an eye insert; or for application on nasal mucosa e.g. a nasal insert, a nasal drop or spray, a nasal ointment or gel.
37. Use according to claim 36 for the preparation of a medicament for topical application in the form of a powder, paste, ointment, lotion, gel, cream, emulsion, solution, suspension, spray, sponge, strip, plaster, pad, or dressing; or for the preparation of a medicament for implantation.
38. Use according to claim 35 for the preparation of a medicament for injection or systemic administration, characterized in that the medicament is in a form suitable for injection or systemic administration, e.g. a solution or a suspension.
39. Use according to any of claims 35-38 wherein the concentration of the substance or mixture of substances is present in the medicament in an amount of 0.001-99%, typically 0.01-75%, more typically 0.1-20%, especially 1-10% by weight of the medicament.
40. Method for treating or preventing disorders of the eye related to the axial length of the eye comprising administering to an individual in need thereof a therapeutically effective amount of one or more substances selected from the group of compounds of the general formula I, II or III
wherein R1, R3, R7, and R9 are independently selected from the group consisting of hydrogen, optionnally substituted C1-20-alkyl, optionally substituted C2-20-alkenyl, optionally substituted C4-20-alkadienyl, optionally substituted c6-20-alkatrienyl, optionally substituted C2-20-alkynyl, optionally substituted C1-20-alkoxycarbonyl, optionally substituted C1-20-alkylcarbonyl, formyl, optionally substituted aryl, optionally substituted aryloxycarbonyl, optionally substituted arylcarbonyl, optionally substituted heteroaryl, optionally substituted heteroaryloxycarbonyl, optionally substituted heteroarylcarbonyl, carbamoyl, mono- and di(C1-20-alkyl)aminocarbonyl, mono- and di(C1-20-alkyl)amino-C1-20-alkyl-aminotarbonyl, and halogen such as fluoro, chloro, bromo or iodo, and
R8 is selected from the group consisting of hydrogen, optionally substituted C1-20-alkyl, optionally substituted C2-20-alkenyl, optionally substituted C4-20-alkadienyl, optionally substituted C6-20-alkatrienyl, optionally substituted C2-20-alkynyl, optionally substituted C1-20-alkoxy, optionally substituted C2-20-alkenyloxy, carboxy, hydroxy, optionally substituted C1-20-alkoxycarbonyl, optionally substituted C1-20-alkylcarbonyl, formyl, optionally substituted aryl, optionally substituted aryloxycarbonyl, optionally substituted aryloxy, optionally substituted arylcarbonyl, optionally substituted arylcarbonyl, optionally substituted heteroaryl, optionally substituted heteroaryloxycarbonyl, optionally substituted heteroaryloxy, optionally substituted heteroarylcarbonyl, amino, mono- and di(C1-20-alkyl)amino, carbamoyl, mono- and di(C1-20-alkyl)aminocarbonyl, amino-C1-20-alkylaminocarbonyl, mono- and di(C1-20-alkyl)amino-C1-20-alkylaminocarbonyl, optionally substituted C1-20-alkylcarbonylamino, guanidino, carbamido, optionally substituted C1-20-alkanoyloxy, sulphono, optionally substituted C1-20-alkylsulphonyloxy, nitro, sulphanyl, optionally substituted C1-20-alkylthio, and halogen such as fluoro, chloro, bromo or iodo.
41. Method according to claim 40 , wherein R1, R3, R7, and R9 are independently selected from the group consisting of hydrogen, optionally substituted C1-6-alkyl, optionally substituted C2-6-alkenyl, optionally substituted C2-6-alkynyl, optionally substituted C1-6-alkylcarbonyl, formyl, optionally substituted aryl, optionally substituted arylcarbonyl, optionally substituted heteroaryl, and optionally substituted hetergarylcarbonyl, and
R8 is selected from the group consisting of hydrogen, optionally substituted C1-6-alkyl, optionally substituted C2-6-alkenyl, optionally substituted C2-6-alkynyl, optionally substituted C1-6-alkoxy, optionally substituted C2-6-alkenyloxy, carboxy, hydroxy, optionally substituted C1-6-alkoxycarbonyl, optionally substituted C1-6-alkylcarbonyl, formyl, optionally substituted aryl, optionally substituted aryloxycarbonyl, optionally substituted aryloxy, optionally substituted arylcarbonyl, optionally substituted arylcarbonyl, optionally substituted heteroaryl, optionally substituted helteroaryloxycarbonyl, optionally substituted heteroaryloxy, optionally substituted heteroarylcarbonyl, amino, mono- and di(C1-6-alkyl)amino, carbamoyl, mono- and di(C1-6-alkyl)aminocarbonyl, optionally substituted C1-6-alkylcarbonylamino, guanidino, carbamido, optionally substituted C1-6-alkanoyloxy, sulphono, optionally substituted C1-6-alkylsulphonyloxy, nitro, sulphanyl, optionally substituted C1-6-alkylthio, and halogen such as fluoro, chloro, bromo or iodo.
42. The method according to claim 41 , wherein R1, R3, R7 and R9 are independently selected from the group consisting of hydrogen, optionally substituted C1-6-alkyl, optionally substituted C2-6-alkenyl, optionally substituted C2-6-alkynyl, optionally substituted aryl, and
R8 is selected from the group consisting of hydrogen, optionally substituted C1-6-alkyl, optionally substituted C2-6-alkenyl, optionally substituted C2-6-alkynyl, optionally substituted C1-6-alkoxy, optionally substituted C2-6-alkenyloxy, carboxy, hydroxy, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted hetero-arylcarbonyl, amino, nitro, sulphanyl, and halogen such as fluoro, chloro, bromo or iodo.
43. Method for treating and/or preventing myopia of a human eye comprising administering to an individual in need thereof a therapeutically effective amount of one or more substances selected from caffeine; 1,7-dimethylxanthine (paraxanthine), 7-methylxanthine (heteroxanthine), 3-methylxanthine; 1-methylxanthine, isobutylmethylxanthine (IBMX) and derivatives; 1-Hexyl-3,7-dimethylxanthine (pentifylline); 1,7-Dimethyl-xanthine; 1,3-Dipropyl-7-methyl-xanthine; 7-Propylxanthine; 7β-Chloroethyl-1,3-dimethylxanthine; 3,7-Dimethyl-1-propargyl-xanthine; 3-Propylxanthine; 1-(5-Oxohexyl)-3,7-dimethylxanthine (pentoxyfylline); 3-Isobutyl-1-methylxanthine; 3,9-Dimethylxanthine 8-Cyclopentyl-1,3-dimethylxanthine; 1,3-Bis(3-methylbut-2-butenyl-7-methylxanthine; 3,7-Dihydro-7-methyl-1,3-dipropyl-1H-purine-2,6-dione; 7-Methyl-1,3-diprenylxanthine(7-methyl-1,3-dipropyl-xanthine; 7-Ethoxymethyl-1-(5-hydroxy-5-methylhex-methylxanthine (Torbafylline, “HWA 448”); 1-(5 hydoxy-5-methylhexyl)-3-methyl-7-propylxanthine (A 80.2715); 3,7-Dimethyl-1-(5-oxyhexyl)-xanthine (Pentoxifylline, “Trental”); 3,7-Dimethyl-1-(5-hydroxyhexyl)-xanthine (Hydroxypentoxifylline); 1-Hexyl-3,7-dimethylxanthine (Pentifylline, “Cosaldon”); 3,7-Dimethyl-1-proparglyxanthine (DMPX); (E)-8-(3,4-Dimethoxystyryl)-1,3-dipropyl-7-methylxanthine (KF 17837)(Lisofylline); 1-(5-Hydroxy-5-methylhexyl)-3-methylxanthine (Albifylline, “HWA 138”): 3-Methyl-1-(5′-oxohexyl)-7-propylxanthine (Propeptofylline, “HWA 285”); 1-(5-Hydroxyhexyl)-3,7-dimethylxanthine (BL 194); (E)-1,3-dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine (KF 17.837); 1,3-di-n-butyl-7-(2′oxopropyl)-xanthine (Denbufylline); 1-n-butyl-3-n-propylxanthine (XT-044); 7-(2,3-dihydroxypropyl)-theophylline (Dyphylline); 7-Methyl-8-(2-hydroxy-N-methylethylamino)-theophylline (Cafaminol); 7-(1,3-Dioxolan 2-ylmethyl)-theophylline (Doxofylline); 7-(2-Hydroxyethyl)-1,3-dimethylxanthine (Etofylline); 7-(2-Hydroxypropyl)-1,3-dimethylxanthine (Proxyphylline); Pyridoxine-O-(theophyllin-7-ylethyl)sulphate (Pyridofylline); 7-(2-(3-diethylcarbamoylpropionyloxy)ethyl)theophylline (Suxamidofylline); Piperazine bis (theophyllin-7-ylacetate)(Acepifylline); 8-benzyl-7-(2-(N-ethyl-N-2-hydroxyethylamino)ethyl)theophylline (Bamifylline); 2-amino-2-methylpropan-1-ol theophyllinate (Bufylline); 7-(2,3-Dihydroxypropyl)-1,3-dimethylxanthine (Diprophylline); 7-(2-diethylamoinoethyl)-1,3-dimethylxanthine camphor 10 sulphonate (Etamiphylline Camsylate); 3-Propylxanthine (Enprofylline); 4-amino-8-chloro-1-phenyl-(1,2,4)-triazolo (4,3-a)quinoxaline (CP 71366);
cysteine/cystine; glycine; forskoline; alpha-2-adrenergic agonist such as brimonidine (UK-14,304), clonidine, apraclonidine, dapiprazole, moxonidine (4-chloro-N-(4,5dihydro-1H-imidasol-2yl)-6-methoxy-2-methyl-5-pyridinamine), medetomidine, oxymetazoline, or derivatives thereof; peptides such as bradykinin, arginine vasopressin including V2 agonists, bombesine, substance P, pituitary adenylate cyclase activating polypeptide; somatostatftin analogues: such as tyril-somatostatin-14, Leu8,D-Trp22, and Tyr25-somatostatin-28 including agonists of somatostatin sst2 receptors, neuropeptide Y including agonists of Y2 receptors, and anlogues of these peptides; calcitriol or analogues of calcitriol or Vitamin D; muscarine receptor agonists such as the Carbachol, acetylincholine or analogues thereof; nonsteroidal anti-inflammatory drugs such as niflumic acid; prostaglandine and analogues thereof such as F2-alpha analogues inciuding PhXA41 (latanoprost), prostaglandin receptor agonists including PGF 2 alpha, 17-phenyl trinor PGE2, and U46619 FP, EP1, and TP receptor agonists), UF 021, 16-phenoxy-PGF2 alpha, cloprostenol, 17-phenyl-PGF2 alpha, fluprostenol, and PhXA85; Thapsigargin, A23187, Phosphodiesterase inhibitors including rolipram and Zaprinast, 4-chloro-3-ethylphenol and Bastidin, veratridine, esterogens including analogues thereof; Bay K 8644 (1,4-Dihydro-2,6-dimethyl-5-nitor-4-(2(triflouromethyl)-phenyl)-3-pyridinencarboxylic acid methyl ester; angiotensin converting enzyme inhibitors, in particular captopril (SQ 14225); adenosine A2-receptor agonists such as 5(N-ethyl)-.carboxamido adenosine -and-8-phenylaminoadenosine (CV-1808); Candoxatril (neutral endopeptidase 24.11 (NEP) inhibitor) Met-enkephalin, alphaendorphin or derivatives; and mixtures thereof.
44. The method for treating or preventing myopia according to claim 43 comprising a mixture of two or more substances having a synergistic effect on the myopia.
45. The method for treating or preventing myopia according to any of claims 43 and 44 comprising caffeine or derivative thereof wherein the caffeine or the derivative thereof is administered in a dosage of 7.5-750 mg 1-4 times daily.
46. The method for treating or preventing myopia according to any of claims 43-44 comprising cystein/cystin wherein the cystein/cystin is administered in a dosage of 20-2000 mg 1-4 times daily.
47. The method for treating or preventing myopia according to any of claims 43-44 comprising forskoline wherein the forskoline is administered in a dosage of 5-560 mg 1-4 times daily.
48. Method for treating and/or preventing hypermetropia of a human eye comprising administering to an individual in need thereof a therapeutically effective amounts of one or more substances selected from-theophylline; 3,7-dimethylxanthine (theobromine), xanthine; 1,9-dimethylxanthine; 1,3-Dipropyl-8-(2-(5,6-epoxynorbonyl)-xanthine; 8-Cyclopentyl-l,3-dipropylxanthine (CPDPX); 8-Sulphophenyltheophylline; 1,3-Dipropyl-8-(4-acrylate)phenylxanthine (BW-A1433); (1-Propyl-11C)8-dicyclopropylmethyl-1,3-dipropylxanthine (11C)KFP15372 and 11C-ethyl and 11C-methyl derivatives thereof; 8-Benzyl-7, (2-(ethyl(2-hydroxyethyl)amino)ethyl)theo-phylline (Bamiphylline); 8-Cyclopentyl-3-(3-((4-(flourosulfonyl)benzoyl)oxyl)pro-pyl)-1-propylxanthine; 1,3-Dipropyl-8-(4-((2-aminoethyl)amino)carbonylmethyl-oxyphenyl)xanthine; 8-(3-chlorostyryl)caffeine; 8-cyclopentyltheophylline; 8-(noradamantan-3 yl)-1,3-dipropylxanthine (KW-3902); 1,3-Dipropyl-8-(3-noradamantyl)-xanthine; 1,3-Dipropyl-8-(4-sulphpphenyl)-xanthine; 1,3-Dipropyl-8-(2-amino-4-chlorophenyl)-xanthine; 7β-Hydroxyethyl-1,3-dimethylxanthine; 7-(2,3-Dihydroxypropyl)-1,3-dimethylxanthine; 8-Chloro-1,3-dimethylxanthine; 1,3,9-Trimethylxanthine; 8-Propionic acid-1,3-dimethylxanthine; 7,9-Dimethylxanthine; 8-Phenyl-1,3-dimethylxanthine; 7-Acetic acid-1,3-dimethylxanthine; 9-Propylxantine; 9-Methlxanthne; 8-Methylxanthine; 8-(p-Sulfophenyl)-1,3-dimethylxanthine; 1,9-Dimethylxanthine; hypoxanthine; ethylendiamin; fluoxetine; L-ornithine; azetazolamid; bumetanide; Tamoxifen and other estrogen antagonists, the calmodulin antagonist J8, calcium antagonists including nimodipine and nicardipine, Endothelin agonist, in particular sarafotoxin S6c (selective ETB receptor agonist); Dorzolamide (MK-507), sezolamide and MK-927 (thienothiopyran-2-sulfonamide derivatives carbonic anhydrase inhibitors), methazolamide, ethoxzolamide, leuenkephalin or dervatives; and mixtures thereof.
49. Method according to claim 48 comprising a mixture of two or more substances having a synergistic effect on the hypermetropia.
50. The method for treating or preventing hypermetropia according to any of claims 48-49 comprising L-orhinthine wherein the L-ornithine is administered in a dosage of 20-2000 mg 1-4 times daily.
51. The method for treating or preventing hypermetropia according any of claims 48-49 comprising fluoxetin wherein the fluoxetin is administered in a dosage of 0.1-20 mg 1-4 times daily.
52. The method for treating or preventing hypermetropia according any of claim 43-46 comprising azetozolamid wherein the azetazolamid is administered in a dosage of 5-500 mg 1-4 times daily.
53. The method for treating or preventing hypermetropia according to any of claims 48-52 wherein theophylline and/or the 3-methylxanthin and/or 1-methylxanthine and/or xanthine is/are administered in a dosage of 7.5-750 mg 1-4 times daily.
54. A method according to any of the preceeding claims wherein the substance is administered systemically.
55. Pharmaceutical preparation for treating and/or preventing myopia of a human eye comprising a therapeutically effective amount of one or more substances selected from caffeine; 1,7-dimethylxanthine (paraxanthine), 7-methylxanthine (heteroxanthine) isobutylmethylxanthine (IBMX) and derivatives; 3-methylxanthine, 1-methylxanthine; 1-Hexyl3,7-dimethylxanthine (pentifylline); 1,7-Dimethyl-xanthine; 1,3-Dipropyl7-methyl-xanthine; 7-Propylxanthine; 7β-Chloroethyl-1,3-dimethylxanthine; C 3,7-Dimethyl-1-propargyl-xanthine, 3-Propylxanthine; 1-(5-Oxohexyl)-3,7-dimethylxanthine (pentoxyfylline); 3-Isobutyl-1-methylxanthine; 3,9-Dimethylxanthine 8-Cyclopentyl-1,3-dimethylxanthine; 1,3-Bis(3-methylbut-2-butenyl-7-methylxanthine; 3,7-Dihydro-7-methyl-1,3-dipropyl-1H-purine-2,6-dione; 7-Methyl-1,3-diprenylxanthine(7-methyl-1,3-dipropyl-xanthine; 7-Ethoxymethyl-1-(5-hydroxy-5-methylhex-methylxanthine (Torbafylline, “HWA 448”); 1-(5 hydoxy-5-methylhexyl)-3-methyl-7-propylxanthine (A 80.2715); 3,7-Dimethyl-1-(5-oxyhexyl)-xanthine (Pentoxifylline, “Trental ”); 3,7-Dimethyl-1-(5-hydroxyhexyl)-xanthine (Hydroxypentoxifylline); 1-Hexyl-3,7-dimethylxanthine (Pentifylline, “Cosaldon”); 3,7-Dimethyl-1-proparglyxanthine (DMPX); (E)-8-(3,4-Dimethoxystyryl)-1,3-dipropyl-7-methylxanthine (KF 17837)(Lisofylline); 1-(5-Hydroxy-5-methylhexyl)-3-methylxanthine (Albifylline, “HWA 138”): 3-Methyl-1-(5′-oxohexyl)-7-propylxanthine (Propentefylline, “HWA 285”); 1-(5-Hydroxyhexyl)-3,7-dimethylxanthine (BL 194); (E)-1,3-dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine (KF 17.837); 1,3-di-n-butyl-7-(2′oxopropyl)-xanthine (Denbufylline); 1-n-butyl-3-n-propylxanthine (XT-044); 7-(2,3-dihydroxypropyl)-theophylline (Dyphylline); 7-Methyl-8-(2-hydroxy-N-!methylethylamino)-theophylline (Cafaminol); 7-(1,3-Dioxolan 2-ylmethyl)-theophylline (Doxofylline); 7-(2-Hydroxyethyl)-1,3-dimethylxanthine (Etofylline); 7-(2-Hydroxypropyl)-1,3-dimethylxanthine-(Pyoxypylline); Pyridoxine-O-(theophyllin-7-ylethyl)sulphate (Pyridofylline); 7-(2-(3-diethylcarbamoylpropionyloxy)ethyl)theophylline (Suxamidofylline); Piperazine bis (theophyllin-7-ylacetate)(Acepifylline); 8-benzyl-7-(2-(N-ethyl-N-2-hydroxyethylamino)ethyl)theophylline (Bamifylline); 2-amino-2-methylpropan-1-ol theophyllninate (Bufylline); 7-(2,3-Dihydroxypropyl)-1,3-dimethylxanthine (Diprophylline); 7-(2-diethylamoinoethyl)-1,3-dimethylxanthine camphor 10 sulphonate (Etamiphylline Camsylate); 3-Propylxanthine (Enprofylline); 4-amino-8-chloro-1-phenyl-(1,2,4)-triazolo (4,3-a)quinoxaline (CP 71366); cysteine/cystine; glycine; forskoline; alpha-2-adrenergic agonist such as brimonidine (UK-14,304), clonidine, apraclonidine, dapiprazole, moxonidine (4-chloro-N-(4,5 dihydro-1H-imidasol-2yl)-6-methoxy-2-methyl-5-pyridinamine), medetomidine, oxymetazoline, or derivatives thereof; peptides such as bradykinin, arginine vasopressin including V2 agonists, bombesine, substance P, pituitary adenylate cyclase activating polypeptide; somatostatin analogues such as Tyril-somatostatin-14, Leu8,D-Trp22, and Tyr25-somatostatin-28 including agonists of somatostatin sst2 receptors, neuropeptide Y including agonists of Y2 receptors, and anlogues of these peptides; calcitriol or analogues of calcitriol or Vitamin D; muscarine receptor agonists such asgthe Carbachol, acetylincholine or analogues thereof; nonsteroidal anti-inflamtmatory drugs such as niflumic acid; prostaglandine and analogues thereof such as F2 alpha analogues including PhXA41 (latanoprost), prostaglandin receptor agonists including PGF 2 alpha, 17-phenyl trinor PGE2, and U46619 FP, EP1, and TP receptor agonists), UF 021, 16-phenoxy-PGF2 alpha, cloprostenol, 17-phenyl-PGF2 alpha, fluprostenol, and PhXA85; Thapsigargin, A23187, Phosphodiesterase inhibitors including rolipram and Zaprinast, 4-chloro-3-ethylphenol and Bastidin, veratridine, esterogens including analogues thereof; Bay K 8644 (1,4-Dihydro-2,6-dimethyl-5-nitor-4-(2(triflouromethyl)-,Phenyl)-3-pyridinencarboxyllc acid methyl ester; angiotensin converting enzyme inhibitors, in particular captopril (SQ 14225); adenosine A2-receptor agonists such as 5′(N-ethyl)-carboxamido adenosine and 8-pheniylaminoadenosine (CV-1808); Candoxatril (neutral endopeptidase 24.11 (NEP) inhibitor); Met-enkephalin, alphaendorphin or derivatives; and mixtures thereof. and mixtures thereof together with a pharmaceutically acceptable carrier or excipient.
56. Pharmaceutical preparation for treating and/or preventing hypermetropia of a human eye comprising a therapeutically effective amount of one or more substances selected from theophylline; 3,7-dimethylxanthine (theobromine); xanthine; 1,9-dimethylxanthine; 1,3-Dipropyl-8-(2-(5,6-epoxynorbonyl)-xanthine; 8-Cydlopentyl-1,3-dipropylxanthinle (CPDPX); 8-Sulphophenyltheophylline; 1,3-Dipropyl-8-(4-acrylate)phenylxanthine (BW-A1433); (1-Propyl-11C) 8-dicyclopropylmethyl-1,3-dipropylxanthine (11C)KF15372 and 11C-ethyl and 11C-methyl derivatives thereof; 8-Benzyl-7,(2-(ethyl(2-hydroxyethyl)amino)ethyl)theo-phylline (Bamiphylline); 8-Cyclopentyl-3-(3-((4-(flourosulfonyl)benzoyl)oxyl)pro-pyl)-1-propylxanthine; 1,3-Dipropyl-8-(4-((2-aminoethyl)amino)carbonylmethyl-oxyphenyl)xanthine; 8-(3-chlorostyryl)caffeine; 8-cyclopentyltheophylline; 8-(noradamantan-3 yl)-1,3-dipropylxanthine (KW-3902); 1,3-Dipropyl-8-(3-noradamantyl)-xanthine; 1,3-Dipropyl-8-(4-sulphophenyl)-xanthine; 1,3-Dipropyl-8-(2-amino-4-chlorophenyl)-xanthine; ethylendiamin; xanthine; hypoxanthine; fluoxetine; L-ornithine; azetazolamid; bumetanide; Tamoxifen and other estrogen antagonists, the calmodulin antagonist J8, calcium antagonists including nimodipine and nicadipine, Endothelin agonist, in particular sarafotoxin S6c (selective -ETB receptor agonist); Dorzolamide (MK-507), sezolamide and MK-927 (thienothiopyran-2-sulfonamide derivatives carbonic anhydrase inhibitors), methazolamide, ethoxzolamide, leuenkephalin or dervatives; and mixtures thereof together with a pharmaceutically acceptable carrier or excipient.
57. Pharmaceutical preparation according to any of claims 55 and 56 in the form suitable for application on mucosa e.g. for application on eye mucosa e.g. eye drops, eye salve, eye gel, or an eye insert; or for application on nasal mucosa e.g. a nasal insert, a nasal drop-or spray, a nasal ointment or gel.
58. Pharmaceutical preparation according to any of claims 55 and 56 in the form suitable for topical application on skin e.g. a powder, paste, ointment, lotion, gel, cream, emulsion, solution, suspension, spray, sponge, strip, plaster, pad, or dressing.
59. Pharmaceutical preparation according to any of claims 55 and 56 in a form suitable for implantation, injection or systemic administration.
60. Pharmaceutical preparation according to any of claims 55 and 56 in a form suitable for injection or systemic administration, e.g. a solution or a suspension.
61. Pharmaceutical preparation according to any of claims 55-60 wherein the concentration of the substance or the mixture of substances is present in the medicament in an amount of 0.001-99%, typically 0.01-75%, more typically 0.1-20%, especially 1-10% by weight of the medicament.
62. Pharmaceutical preparation according to any of claims 55-61 wherein the substance or the mixture of substance are extracted from natural sources.
63. Use of a compound of the general formula I, II or III
wherein R1, R3, R7, and R9 are independently selected from the group consisting of hydrogen, optionally substituted C1-20-alkyl, optionally substituted C2-20-alkenyl, optionally substituted C4-20-alkadienyl, optionally substituted C6-20, alkatrienyl, optionally substituted C2-20 alkynyl, optionally substituted C1-20-alkcxycarbonyl, optionally substituted C1-20-alkylcarbonyl, formyl, optionally substituted aryl, optionally substituted aryloxycarbonyl, optionally substituted arylcarbonyl, optionallysubstituted he teroaryl, optionally substituted heteroaryloxycarbonyl, optionally substituted heteroarylcarbonyl, carbamoyl, mono- and di(C1-20-alkyl)aminocarbonyl, mono- and di(C1-20-alkyl)amino-C1-20-alkyl-aminocarbonyl, and halogen such as fluoro, chloro, bromo or iodo, and
R8 is selected from the group consisting of hydrogen, optionally substituted C1-20-alkyl, optionally substituted C2-20-alkenyl, optionally substituted C4-20-alkadienyl, optionally substituted C6-20-alkatrienyl, optionally substituted C2-20-alkynyl, optionally substituted C1-20-alkoxy, optionally substituted C2-20-alkenyloxy, carboxy, hydroxy, optionally substituted C1-20-alkoxycarbonyl, optionally substituted C2-20-alkylcarbonyl, formyl, optionally substituted aryl, optionally substituted aryloxycarbonyl, optionally substituted aryloxy, optionally substituted arylcarbonyl, optionally substituted arylcarbonyl, optionally substituted heteroaryl, optionally substituted heteroaryloxycarbonyl, optionally substituted heteroaryloxy, optionally substituted heteroarylcarbonyl, amino, mono- and di(C1-20-alkyl)amino, carbamoyl, mono- and di(C1-20-alkyl)aminocarbonyl, amino-C1-20-alkylaminocarbonyl, mono- and di(C1-20-alkyl)amino-C1-20-alkylaminocarbonyl, optionally substituted C1-20-alkylcarbonylamino, guanidino, carbamido, optionally substituted C1-20-alkanoyloxy, sulphono, optionally substituted C1-20-alkylsulphonyloxy, nitro, sulphanyl, optionally substituted C1-20-alkylthio, and halogen such as fluoro, chloro, bromo or iodo for the preparation of a medicament for treating or preventing disorders of the eye related to the axial length of the eye.
64. Use according to claim 63 , wherein R1, R3, R7, and R9 are independently selected from the group consisting of hydrogen, optionally substituted C1-6-alkyl, optionally substituted C2-6-alkenyl, optionally substituted C2-6alkynyl, optionally substituted C1-6-alkylcarbonyl, formyl, optionally substituted aryl, optionally substituted arylcarbonyl, optionally substituted heteroaryl, and optionally substituted heteroarylcarbonyl, and
R8 is selected from the group consisting of hydrogen, optionally substituted C1-6-alkyl, optionally substituted C2-6-alkenyl, optionally substituted C2-6-alkynyl, optionally substituted C1-6-alkoxy, optionally substituted C2-6-alkenyloxy, carboxy, hydroxy, optionally substituted C1-6-alkoxycarbonyl, optionally substituted C1-6-alkylcarbonyl, formyl, optionally substituted aryl, optionally substituted aryloxycarbonyl, optionally substituted aryloxy, optionally substituted arylcarbonyl, optionally substituted arylcarbonyl, optionally substituted heteroaryl, optionally substituted heteroaryloxycarbonyl, optionally substituted heteroaryloxy, optionally substituted heteroarylcarbonyl, amino, mono- and di(C1-6-alkyl)amino, carbamoyl, mono- and di(C1-6-alkyl)amninocarbonyl, optionally substituted C1-6-alkylcarbonylamino, guanidino, carbamido, optionally substituted C1-6-alkanoyloxy, sulphono, optionally substituted C1-6-alkylsulphonyloxy, nitro, sulphanyl, optionally substituted C1-6-alkylthio, and halogen such as fluoro, chloro, bromo or iodo.
65. Use according to claim 64 , wherein R1, R3, R7 and R9 are independently selected from the group consisting of hydrogen, optionally substituted C1-6-alkyl, optionally substituted C2-6-alkenyl, optionally substituted C2-6-alkynyl, optionally substituted aryl, and
R8 is selected from the group consisting of hydrogen, optionally substituted C1-6-alkyl, optionally substituted C2-6-alkenyl, optionally substituted C2-6-alkynyl, optionally substituted C1-6-alkoxy, optionally substituted C2-6-alkenyloxy, carboxy, hydroxy, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heteroarylcarbonyl, amino, nitro, sulphanyl, and halogen such as fluoro, chloro, bromo or iodo.
66. Use according to any of claims 63-65 wherein the preparation is in the form suitable for application on mucosa e.g. for application on eye mucosa e.g. eye drops, eye salve, eye gel, or an eye insert; or for application on nasal mucosa e.g. a nasal insert, a nasal drop or spray, a nasal ointment or gel.
67. Use according to any of claims 63-65 wherein the preparation is in the form suitable for topical application on skin e.g. a powder, paste, ointment, lotion, gel, cream, emulsion, solution, suspension, spray, sponge, strip, plaster, pad, or dressing.
68. Use according to any of claims 63-65 wherein the preparation is in a form suitable for implantation, injection or systemic administration.
69. Use according to any of claims 63-68 wherein the substance or the mixture of substances is present in the medicament in an amount of 0.001-99%, typically 0.01-75%, more typically 0.1-20%, especially 1-10% by weight of the medicament.
70. Use according to any of claims 63-68 wherein the xanthine or substituted xanthine is present in a dosage of 7.5-750 mg and is administered 1-4 times daily.
71. Use according to any of claims 63-70 excluding an implantat of claim 68
wherein the medicament is intended for administration 1-4 times daily.
72. Use-according to any of claims 63-71 wherein the substance or the mixture of substances are extracted from natural sources.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/464,750 US20040013609A1 (en) | 1997-01-06 | 2003-06-19 | Screening method |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK0009/97 | 1997-01-06 | ||
DK997 | 1997-01-06 | ||
DK82397 | 1997-07-07 | ||
DK0823/97 | 1997-07-07 | ||
DK1383/97 | 1997-12-01 | ||
DK138397 | 1997-12-01 | ||
US09/341,169 US6710051B1 (en) | 1997-01-06 | 1998-01-05 | Screening method |
US10/464,750 US20040013609A1 (en) | 1997-01-06 | 2003-06-19 | Screening method |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK1998/000001 Division WO1998030900A2 (en) | 1997-01-06 | 1998-01-05 | Screening method for compounds active in treating myopia and hypermetropia |
US09/341,169 Division US6710051B1 (en) | 1997-01-06 | 1998-01-05 | Screening method |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040013609A1 true US20040013609A1 (en) | 2004-01-22 |
Family
ID=27220325
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/341,169 Expired - Lifetime US6710051B1 (en) | 1997-01-06 | 1998-01-05 | Screening method |
US10/464,750 Abandoned US20040013609A1 (en) | 1997-01-06 | 2003-06-19 | Screening method |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/341,169 Expired - Lifetime US6710051B1 (en) | 1997-01-06 | 1998-01-05 | Screening method |
Country Status (4)
Country | Link |
---|---|
US (2) | US6710051B1 (en) |
AU (1) | AU5312198A (en) |
CA (1) | CA2276287C (en) |
WO (1) | WO1998030900A2 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9375478B1 (en) | 2015-01-30 | 2016-06-28 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9687526B2 (en) | 2015-01-30 | 2017-06-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9744209B2 (en) | 2015-01-30 | 2017-08-29 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9750785B2 (en) | 2015-01-30 | 2017-09-05 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9919026B2 (en) | 2015-01-30 | 2018-03-20 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9937223B2 (en) | 2015-01-30 | 2018-04-10 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US20200345633A1 (en) * | 2017-11-03 | 2020-11-05 | Brien Holden Vision Institute Limited | Pharmaceutical Compositions for Controlling and/or Reducing the Progression of Myopia |
US10912456B2 (en) * | 2016-01-27 | 2021-02-09 | Johnson & Johnson Vision Care, Inc. | Ametropia treatment tracking methods and system |
US11786694B2 (en) | 2019-05-24 | 2023-10-17 | NeuroLight, Inc. | Device, method, and app for facilitating sleep |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6734211B1 (en) * | 1999-07-09 | 2004-05-11 | Oregon Health & Sciences University | Compositions and methods for promoting nerve regeneration |
MXPA02007039A (en) * | 2000-01-18 | 2003-09-25 | Univ Pennsylvania | Ocular growth and nicotinic antagonists. |
SE0002211D0 (en) * | 2000-06-13 | 2000-06-13 | Synphora Ab | Methods and compositions for prevention of myopia |
PL366372A1 (en) | 2001-07-17 | 2005-01-24 | Pharmacia & Upjohn Company | Process and intermediates to prepare latanoprost |
MXPA03011987A (en) | 2003-12-19 | 2005-06-23 | Osio Sancho Alberto | Method for treating presbyopia by inducing changes in the corneal power and physiology. |
WO2005079781A1 (en) * | 2004-02-25 | 2005-09-01 | La Trobe University | Therapeutic and/or prophylactic method |
PE20060272A1 (en) * | 2004-05-24 | 2006-05-22 | Glaxo Group Ltd | (2R, 3R, 4S, 5R, 2'R, 3'R, 4'S, 5'S) -2.2 '- {TRANS-1,4-CYCLOHEXANODIYLBIS- [IMINO (2 - {[2- (1-METHYL- 1H-IMIDAZOL-4-IL) ETHYL] AMINO} -9H-PURIN-6,9-DIYL)]} BIS [5- (2-ETHYL-2H-TETRAZOLE-5-IL) TETRAHYDRO-3,4-FURANODIOL] AS AN A2A AGONIST |
GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
EP2114238A1 (en) * | 2007-02-14 | 2009-11-11 | The Institute For Eye Research Limited | Characterization of optical systems |
US8986253B2 (en) | 2008-01-25 | 2015-03-24 | Tandem Diabetes Care, Inc. | Two chamber pumps and related methods |
US7884228B1 (en) | 2008-05-06 | 2011-02-08 | Alcon, Inc. | UV-absorbers for ophthalmic lens materials |
US8408421B2 (en) | 2008-09-16 | 2013-04-02 | Tandem Diabetes Care, Inc. | Flow regulating stopcocks and related methods |
EP2334234A4 (en) | 2008-09-19 | 2013-03-20 | Tandem Diabetes Care Inc | Solute concentration measurement device and related methods |
US8236053B1 (en) | 2008-10-08 | 2012-08-07 | Novartis Ag | 2-amino benzophenone UV-absorbers for ophthalmic lens materials |
TWI453199B (en) | 2008-11-04 | 2014-09-21 | Alcon Inc | Uv/visible light absorbers for ophthalmic lens materials |
US9211377B2 (en) | 2009-07-30 | 2015-12-15 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
ES2752008T3 (en) * | 2009-10-30 | 2020-04-02 | Intratus Inc | Methods and compositions for sustained drug release |
US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
KR102184340B1 (en) | 2012-08-10 | 2020-12-01 | 오시오 코포레이션 디/비/에이 율리아 헬스 | Contact lens use in the treatment of an ophthalmologic condition |
US10357606B2 (en) | 2013-03-13 | 2019-07-23 | Tandem Diabetes Care, Inc. | System and method for integration of insulin pumps and continuous glucose monitoring |
US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
CN105998030A (en) * | 2016-05-17 | 2016-10-12 | 温州医科大学 | Application of prostaglandin F2a receptor stimulant in preparation of drug for inhibiting myopia and application method of prostaglandin F2a receptor stimulant |
USD875765S1 (en) | 2018-08-10 | 2020-02-18 | Tandem Diabetes Care, Inc. | Display screen or portion thereof with graphical user interface |
USD875766S1 (en) | 2018-08-10 | 2020-02-18 | Tandem Diabetes Care, Inc. | Display screen or portion thereof with graphical user interface |
USD880496S1 (en) | 2018-08-20 | 2020-04-07 | Tandem Diabetes Care, Inc. | Display screen or portion thereof with graphical user interface |
USD864218S1 (en) | 2018-08-20 | 2019-10-22 | Tandem Diabetes Care, Inc. | Display screen or portion thereof with graphical user interface |
USD864217S1 (en) | 2018-08-20 | 2019-10-22 | Tandem Diabetes Care, Inc. | Display screen or portion thereof with graphical user interface |
USD864219S1 (en) | 2018-08-20 | 2019-10-22 | Tandem Diabetes Care, Inc. | Display screen or portion thereof with graphical user interface |
USD882622S1 (en) | 2018-08-22 | 2020-04-28 | Tandem Diabetes Care, Inc. | Display screen or portion thereof with graphical user interface |
USD875767S1 (en) | 2018-08-23 | 2020-02-18 | Tandem Diabetes Care, Inc. | Display screen or portion thereof with graphical user interface |
USD931306S1 (en) | 2020-01-20 | 2021-09-21 | Tandem Diabetes Care, Inc. | Display screen or portion thereof with graphical user interface |
EP4210690A1 (en) * | 2020-09-11 | 2023-07-19 | Intratus-Nevada, Inc. | Compositions and methods for treating presbyopia, hyperopia, astigmatism, decreased stereopsis, and decreased contrast sensitivity |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4425346A (en) * | 1980-08-01 | 1984-01-10 | Smith And Nephew Associated Companies Limited | Pharmaceutical compositions |
US4942161A (en) * | 1988-02-25 | 1990-07-17 | Heinfried Tiburtius | Use of beta blockers for the treatment of the progression of infantile axial myopia |
US5055302A (en) * | 1990-02-22 | 1991-10-08 | Trustees Of The University Of Pennsylvania | Neuropeptide control of ocular growth |
US5122522A (en) * | 1989-06-21 | 1992-06-16 | The Trustees Of The University Of Pennsylvania | Treatment and control of ocular development |
US5521168A (en) * | 1994-10-13 | 1996-05-28 | Alcon Laboratories, Inc. | Estrogen metabolites for lowering intraocular pressure |
US5626865A (en) * | 1991-10-15 | 1997-05-06 | Advanced Corneal Systems, Inc. | Enzyme-orthokeratology |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0737475T3 (en) * | 1989-06-21 | 2001-10-08 | Univ Pennsylvania | Use of a muscarinic antagonist for the manufacture of a medicament for the treatment and regulation of ocular development |
DE4207366C2 (en) | 1991-09-26 | 1996-06-13 | Adalbert Dr Med Obal | Medicines to influence intraocular pressure and a method for obtaining them |
WO1993013777A1 (en) * | 1992-01-21 | 1993-07-22 | Merck & Co., Inc. | Method of using m1-selective antimuscarinic pyridobenzodiazepinones in axial myopia therapy |
US5521210A (en) * | 1993-04-13 | 1996-05-28 | Allergan, Inc. | Ophthalmic use of muscarinic agonists having increased duration of activity |
US5461052A (en) * | 1993-04-30 | 1995-10-24 | The Trustees Of The University Of Pennsylvania | Prevention of myopia by tricyclic compounds |
-
1998
- 1998-01-05 WO PCT/DK1998/000001 patent/WO1998030900A2/en active Application Filing
- 1998-01-05 US US09/341,169 patent/US6710051B1/en not_active Expired - Lifetime
- 1998-01-05 CA CA002276287A patent/CA2276287C/en not_active Expired - Lifetime
- 1998-01-05 AU AU53121/98A patent/AU5312198A/en not_active Abandoned
-
2003
- 2003-06-19 US US10/464,750 patent/US20040013609A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4425346A (en) * | 1980-08-01 | 1984-01-10 | Smith And Nephew Associated Companies Limited | Pharmaceutical compositions |
US4942161A (en) * | 1988-02-25 | 1990-07-17 | Heinfried Tiburtius | Use of beta blockers for the treatment of the progression of infantile axial myopia |
US5086061A (en) * | 1988-02-25 | 1992-02-04 | Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh | Use of beta blockers for the treatment of the progression of infantile axial myopia |
US5122522A (en) * | 1989-06-21 | 1992-06-16 | The Trustees Of The University Of Pennsylvania | Treatment and control of ocular development |
US5055302A (en) * | 1990-02-22 | 1991-10-08 | Trustees Of The University Of Pennsylvania | Neuropeptide control of ocular growth |
US5626865A (en) * | 1991-10-15 | 1997-05-06 | Advanced Corneal Systems, Inc. | Enzyme-orthokeratology |
US5521168A (en) * | 1994-10-13 | 1996-05-28 | Alcon Laboratories, Inc. | Estrogen metabolites for lowering intraocular pressure |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9937223B2 (en) | 2015-01-30 | 2018-04-10 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9744209B2 (en) | 2015-01-30 | 2017-08-29 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9962422B2 (en) | 2015-01-30 | 2018-05-08 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9968649B2 (en) | 2015-01-30 | 2018-05-15 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9750785B2 (en) | 2015-01-30 | 2017-09-05 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9919026B2 (en) | 2015-01-30 | 2018-03-20 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9925233B2 (en) | 2015-01-30 | 2018-03-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9925234B2 (en) | 2015-01-30 | 2018-03-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9375478B1 (en) | 2015-01-30 | 2016-06-28 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9687526B2 (en) | 2015-01-30 | 2017-06-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9744239B2 (en) | 2015-01-30 | 2017-08-29 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9974827B2 (en) | 2015-01-30 | 2018-05-22 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9981006B2 (en) | 2015-01-30 | 2018-05-29 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9993520B2 (en) | 2015-01-30 | 2018-06-12 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US10010575B2 (en) | 2015-01-30 | 2018-07-03 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US10912456B2 (en) * | 2016-01-27 | 2021-02-09 | Johnson & Johnson Vision Care, Inc. | Ametropia treatment tracking methods and system |
US20200345633A1 (en) * | 2017-11-03 | 2020-11-05 | Brien Holden Vision Institute Limited | Pharmaceutical Compositions for Controlling and/or Reducing the Progression of Myopia |
US11786694B2 (en) | 2019-05-24 | 2023-10-17 | NeuroLight, Inc. | Device, method, and app for facilitating sleep |
Also Published As
Publication number | Publication date |
---|---|
CA2276287C (en) | 2007-10-30 |
AU5312198A (en) | 1998-08-03 |
WO1998030900A8 (en) | 1999-04-01 |
US6710051B1 (en) | 2004-03-23 |
WO1998030900A2 (en) | 1998-07-16 |
CA2276287A1 (en) | 1998-07-16 |
WO1998030900A3 (en) | 1998-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6710051B1 (en) | Screening method | |
JP6811203B2 (en) | Treatment of diabetes in patients with inadequate glycemic control despite treatment with oral or parenteral antidiabetic drugs | |
US7825102B2 (en) | Treatment of dry eye conditions | |
CA2281562C (en) | Forskolin for promoting lean body mass | |
EP0480934B1 (en) | A slimming pharmaceutical composition | |
KR101750693B1 (en) | Dpp-ⅳ inhibitors for use in the treatment of nafld | |
EP2015754B1 (en) | Uses of dpp-iv inhibitors | |
JPH06192101A (en) | Composition prepared by containing xanthine derivative for locally treating psoriasis and atopy dermatitis | |
EP1688161A1 (en) | Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis | |
KR20070100261A (en) | Treatment of inflammation | |
IL168853A (en) | Use of barbituric acid derivatives in the preparation of a medicament for treating movement disorders | |
TWI702962B (en) | Compositions and methods for lipid metabolism disorder | |
Fredholm et al. | Are the anti-allergic actions of theophylline due to antagonism at the adenosine receptor | |
Karlsson et al. | Neither vasoactive intestinal peptide (VIP) nor purine derivatives may mediate non‐adrenergic tracheal inhibition | |
CN114080222A (en) | Compositions and methods for using trigonelline to produce intracellular nicotinamide adenine dinucleotide (NAD +) for treating or preventing physiological disorders or conditions | |
EP3213751A1 (en) | Phacosclerosis inhibitor | |
EP2217233B1 (en) | Methods and compositions for treating hepatic diseases | |
Smythe et al. | Mechanisms of 5-hydroxy-L-tryptophan-induced adrenocorticotropin release: a major role for central noradrenergic drive | |
KR20050058468A (en) | Adenosine a2a receptor antagonists for treating restless legs syndrome or related disorders | |
JP2020172554A (en) | Treatment for diabetes in patients with insufficient glycemic control despite therapy with oral or non-oral antidiabetic drug | |
KR101971762B1 (en) | A3 adenosine receptor ligands for use in treatment of a sexual dysfunction | |
Saano et al. | Influence of chinoin-170, a novel antitussive, on the mucociliary activity in respiratory airways of rats, rabbits, guinea-pigs and man | |
ITRM20000448A1 (en) | USE OF AN ASSOCIATION OF VITAMINS FOR THE TREATMENT OF PRIMARY HEADACES. | |
CN114126611A (en) | Compositions and methods for producing intracellular NAD + using trigonelline | |
Zhang | Pharmacological effect of caffeine and related purine alkaloids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |